{"protocolSection":{"identificationModule":{"nctId":"NCT04523571","orgStudyIdInfo":{"id":"BNT162-03"},"organization":{"fullName":"BioNTech SE","class":"INDUSTRY"},"briefTitle":"Safety and Immunogenicity of SARS-CoV-2 mRNA Vaccine (BNT162b1) in Chinese Healthy Subjects","officialTitle":"Safety and Immunogenicity of SARS-CoV-2 mRNA Vaccine (BNT162b1) in Chinese Healthy Subjects: A Phase I, Randomized, Placebo-controlled, Observer-blind Study"},"statusModule":{"statusVerifiedDate":"2023-09","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2020-07-28","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2020-09-30","type":"ACTUAL"},"completionDateStruct":{"date":"2021-08-10","type":"ACTUAL"},"studyFirstSubmitDate":"2020-08-18","studyFirstSubmitQcDate":"2020-08-20","studyFirstPostDateStruct":{"date":"2020-08-21","type":"ACTUAL"},"resultsFirstSubmitDate":"2022-08-10","resultsFirstSubmitQcDate":"2023-09-15","resultsFirstPostDateStruct":{"date":"2023-09-18","type":"ACTUAL"},"lastUpdateSubmitDate":"2023-09-15","lastUpdatePostDateStruct":{"date":"2023-09-18","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"BioNTech SE","class":"INDUSTRY"},"collaborators":[{"name":"Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.","class":"INDUSTRY"}]},"oversightModule":{"oversightHasDmc":true,"isFdaRegulatedDrug":false,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"This was a phase I, randomized, placebo-controlled, observer-blind study, for evaluation of safety and immunogenicity of SARS-CoV-2 mRNA vaccine (BNT162b1) in Chinese healthy population.","detailedDescription":"The participants were screened for 2 weeks (Day -14 to Day 0) before randomization, and received 1 dose of SARS-CoV-2 vaccine (BNT162b1) or placebo intramuscularly (IM) on Day 1 and Day 22, respectively. After randomization, the study for each participant lasted for approximately 12 months."},"conditionsModule":{"conditions":["SARS-CoV-2"],"keywords":["Protection against COVID-19","Coronavirus Disease 2019","Coronavirus infection","Vaccine","RNA Vaccine","Virus Diseases"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE1"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"PREVENTION","maskingInfo":{"masking":"TRIPLE","whoMasked":["PARTICIPANT","INVESTIGATOR","OUTCOMES_ASSESSOR"]}},"enrollmentInfo":{"count":144,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Low-dose, 18-55 years of age","type":"EXPERIMENTAL","interventionNames":["Biological: BNT162b1"]},{"label":"High-dose, 18-55 years of age","type":"EXPERIMENTAL","interventionNames":["Biological: BNT162b1"]},{"label":"Placebo, 18-55 years of age","type":"PLACEBO_COMPARATOR","interventionNames":["Other: Placebo"]},{"label":"Low-dose, 65-85 years of age","type":"EXPERIMENTAL","interventionNames":["Biological: BNT162b1"]},{"label":"High-dose, 65-85 years of age","type":"EXPERIMENTAL","interventionNames":["Biological: BNT162b1"]},{"label":"Placebo, 65-85 years of age","type":"PLACEBO_COMPARATOR","interventionNames":["Other: Placebo"]}],"interventions":[{"type":"BIOLOGICAL","name":"BNT162b1","description":"Intramuscular injection","armGroupLabels":["High-dose, 18-55 years of age","High-dose, 65-85 years of age","Low-dose, 18-55 years of age","Low-dose, 65-85 years of age"]},{"type":"OTHER","name":"Placebo","description":"Intramuscular injection","armGroupLabels":["Placebo, 18-55 years of age","Placebo, 65-85 years of age"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Number of Participants With Solicited Local Adverse Events (AEs) (e.g., Injection Site Pain, Redness, Induration, Swelling) Recorded up to 14 Days After Each Dose of BNT162b1 or Placebo.","description":"Solicited local AEs were collected within 7 days/14 days after each vaccination. For the grading of AEs, a 7-day period AE assessment after each dose as graded by United States (US) Food and Drug Administration (FDA) criteria along with the 14-day period AE assessment as graded by National Medical Products Administration (NMPA) criteria are used to evaluate solicited AEs. For other AEs, only the NMPA criteria is used. The \"solicited\" AEs were pre-defined and listed in the subjects' diaries. All the solicited local AEs occurred within 7 days after vaccination were related to investigational vaccine (or placebo).","timeFrame":"Up to 14 days following each dose administration"},{"measure":"Number of Participants With Solicited Systemic AEs (e.g., e.g., Nausea, Vomiting, Diarrhea, Headache, Fatigue, Myalgia, Arthralgia, Chills, Loss of Appetite, Malaise, and Fever) Recorded up to 14 Days After Each Dose of BNT162b1 or Placebo.","description":"Solicited systemic AEs were collected within 7 days/14 days after each vaccination. For the grading of AEs, a 7-day period AE assessment after each dose as graded by US FDA criteria along with the 14-day period AE assessment as graded by NMPA criteria are used to evaluate solicited AEs. For other AEs, only the NMPA criteria is used. The \"solicited\" AEs were pre-defined and listed in the subjects' diaries. Except for 1 event (myalgia) occurred in 10 µg group and 1 event (diarrhea) occurred in placebo group, all the solicited systemic AEs occurred within 7 days after vaccination were related to investigational vaccine (or placebo). All the solicited systemic AEs occurred within 14 days after vaccination were related to investigational vaccine (or placebo), except for 1 event (myalgia) occurred in placebo group and 2 events (both diarrhea; 1 event occurred in 30 µg group, 1 event occurred in placebo group).","timeFrame":"Up to 14 days following each dose administration"},{"measure":"Number of Participants With Unsolicited Vaccine Related AEs During the 21-day Period After Dose 1 of BNT162b1 or Placebo.","description":"AEs occurred during the 21-day period after dose 1 were also referred as \"unsolicited\" AEs. The unsolicited AEs were not pre-defined in the subjects' diaries.","timeFrame":"21-day period after dose 1 vaccination"},{"measure":"Number of Participants With Unsolicited Vaccine Related AEs During the 28-day Period After Dose 2 of BNT162b1 or Placebo.","description":"AEs occurred during the 28-day period after dose 2 were also referred as \"unsolicited\" AEs. The unsolicited AEs were not pre-defined in the subjects' diaries.","timeFrame":"28-day period after dose 2 vaccination"}],"secondaryOutcomes":[{"measure":"The Number of Participants Experiencing Treatment Emergent Serious Adverse Events (TESAEs)","timeFrame":"From Dose 1 up to Month 12"},{"measure":"The Number of Participants Experiencing Related TEAEs","description":"\"Related\" implies the relationship between AE and vaccine is one of \"Possibly related\", \"Probably related\" and \"Definitely related\".","timeFrame":"From Dose 1 up to Month 12"},{"measure":"The Number of Participants Experiencing Clinically Significant (CS) Abnormal Markers of Hematology, Blood Chemistry and Urine Analysis","description":"Results for CS results are displayed by abnormal parameter. Abnormal test results assessed not clinical significant are not presented. Participants with more than one 'CS' parameter are counted for each parameter separately and therefore included multiple times.","timeFrame":"Hour 24 and Day 7 after dose 1 and Day 7 after dose 2"},{"measure":"Geometric Mean Titer (GMT) of Anti-S1 IgG Antibody","description":"At Day 7, Day 21 after dose 1, at Day 7, Day 21 after dose 2, and at Month 3, 6 and 12 after dose 1.","timeFrame":"Up to 12 months following first dose"},{"measure":"GMT of Anti-receptor Binding Domain (RBD) Immunoglobulin G (IgG) Antibody","description":"At Day 7, Day 21 after dose 1, at Day 7, Day 21 after dose 2, and at Month 3, 6 and 12 after dose 1.","timeFrame":"Up to 12 months following first dose"},{"measure":"GMT of SARS-CoV-2 Neutralizing Antibody (Including True Virus-based SARS-CoV-2 Neutralizing Test)","description":"At Day 7, Day 21 after first dose, at Day 7, Day 21 after second dose, and at Month 3, 6, and 12 after first dose.","timeFrame":"Up to 12 months following first dose"},{"measure":"Fold Increase in Antibody Anti-S1 IgG Antibody Titers, as Compared to Baseline","description":"At Day 7, Day 21 after dose 1, at Day 7, Day 21 after dose 2, and at Month 3, 6, and 12 after dose 1.","timeFrame":"Up to 12 months following the first dose"},{"measure":"Fold Increase in Antibody Anti-RBD IgG Antibody Titers, as Compared to Baseline","description":"At Day 7, Day 21 after dose 1, at Day 7, Day 21 after dose 2, and at Month 3, 6, and 12 after dose 1.","timeFrame":"Up to 12 months following first dose"},{"measure":"Fold Increase in SARS-CoV-2 Neutralizing Antibody Titers (Virus Neutralizing Test), as Compared to Baseline.","description":"At Day 7, Day 21 after dose 1, at Day 7, Day 21 after dose 2, and at Month 3, 6, and 12 after dose 1.","timeFrame":"Up to 12 months following first dose"},{"measure":"Seroconversion Rates (SCR) Defined as a Minimum of 4-fold Increase of Antibody Titers, as Compared to Baseline","description":"At Day 7, Day 21 after dose 1, and at Day 7, Day 21 after dose 2.","timeFrame":"Up to 21 days after dose 2"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\nFor adult group (age ≥18 and ≤55)\n\n* Male or female subjects of ≥18 years old and ≤55 years old with body mass index (BMI) ≥18 and ≤30 at the Screening Visit.\n* Individuals who are in good health condition at the time of entry into the trial as determined by medical history, physical examination (including vital signs, electrocardiogram \\[ECG\\]) and eligibility screening test (hematology, blood chemistry and urine analysis) and clinical judgment of the investigator at Screening Visit.\n* The subject can provide with informed consent and signs and dates a written informed consent form (ICF) prior to the initiation of any trial procedures.\n* They must be able to understand and follow trial-related instructions.\n* They must be willing and able to comply with planned visits, treatment schedule, laboratory tests and other requirements of the trial.\n* Negative in antibodies screening of SARS-CoV-2 (fingerstick).\n* Normal in chest computed tomography (CT) scans (no imaging features of COVID-19).\n* Axillary temperature ≤ 37.0ºC.\n* Negative SARS-CoV-2 test in throat swabs by reverse transcription-polymerase chain reaction (RT-PCR).\n* Women of childbearing potential (WOCBP) must have a negative beta-human chorionic gonadotropin (β-hCG) in serum sample at Screening Visit. Women that are postmenopausal (Menopause≥12 consecutive months) or permanently sterilized will be considered as not having reproductive potential.\n* WOCBP must have used effective contraception 14 days prior to screening and agree to use effective contraception continuously during the trial period, from 14 days prior to Screening Visit to 60 days after the last immunization.\n* WOCBP must agree not to donate eggs (ova, oocytes) for the purposes of assisted reproduction during trial, starting from Screening Visit and continuously until 60 days after being given the last immunization.\n* Men who are sexually active with a WOCBP and have not had a vasectomy must agree to practice an effective form of contraception with their female partner of childbearing potential during the trial, starting from Screening Visit and continuously until 60 days after being given the last immunization.\n* Men must be willing to refrain from sperm donation, starting from Screening Visit and continuously until 60 days after receiving the last immunization.\n\nFor the elderly group (age ≥65 and ≤85)\n\n* Male or female subjects ≥65 years old and ≤85 years old at Screening Visit\n* Individuals who are in a health condition that can receive the investigational vaccine, at the time of entry into the trial as determined by medical history, physical examination (including vital signs, ECG) and eligibility screening tests (hematology, biochemistry and urinalysis) and clinical judgment of the investigator at Screening Visit.\n* The subject can provide with informed consent and signs and dates a written ICF prior to the initiation of any trial procedures.\n* They must be able to understand and follow trial-related instructions.\n* They must be willing and able to comply with planned visits, treatment schedule, laboratory tests and other requirements of the trial.\n* Negative in antibodies screening of SARS-CoV-2 (blood sample from fingertip).\n* No imaging features of COVID-19 in chest CT.\n* Axillary temperature ≤ 37.0ºC.\n* Negative SARS-CoV-2 test in throat swabs by RT-PCR.\n* WOCBP must have a negative serum β-hCG at Screening Visit. Women that are postmenopausal (Menopause ≥12 consecutive months) or permanently sterilized will be considered as not having reproductive potential.\n* WOCBP must have used effective contraception 14 days prior to screening and agree to use effective contraception continuously during the trial period, from 14 days prior to Screening Visit to 60 days after the last immunization.\n* WOCBP must agree not to donate eggs (ova, oocytes) for the purposes of assisted reproduction during trial, starting from Screening Visit and continuously until 60 days after being given the last immunization.\n* Men who are sexually active with a WOCBP and have not had a vasectomy must agree to practice an effective form of contraception with their female partner of childbearing potential during the trial, starting from Screening Visit and continuously until 60 days after being given the last immunization.\n* Men must be willing to refrain from sperm donation, starting from Screening Visit and continuously until 60 days after receiving the last immunization.\n\nExclusion Criteria:\n\nFor adult group (age ≥18 and ≤55)\n\n* Have had any acute illness, as determined by the investigator, with or without fever, within 72 hours prior to the prime vaccination. An acute illness which is nearly resolved with only minor residual symptoms remaining is allowable if, in the opinion of the investigator, the residual symptoms will not compromise their well-being if they participate as trial subjects in the trial, or that could prevent, limit, or confound the protocol-specified assessments.\n* Are breastfeeding on the day of Screening Visit or who plan to breastfeed during the trial, starting from Screening Visit and continuously until at least 90 days after the last immunization. Women or partners who plan to become pregnant within 1 year post the Screening Visit.\n* Have a known allergy, hypersensitivity, or intolerance to the planned vaccine for trial including any excipients.\n* Used to have a history of hypersensitivity or serious reactions to vaccination.\n* Received any vaccination within 4 weeks prior to Visit 1.\n* Don't agree to not be vaccinated during the trial, starting from Screening Visit and continuously until 28 days after receiving the last immunization, except emergency vaccination (e.g. rabies vaccine, tetanus vaccine).\n* Had any medical condition (e.g., autoimmune disease) or any major surgery (e.g., requiring general anesthesia) within the past 5 years, which in the opinion of the investigator, could compromise their well-being if they participate as trial subjects in the trial, or that could prevent, limit, or confound the protocol-specified assessments.\n* Have any surgery planned during the trial, starting from Screening Visit and continuously until at least 90 days after the last immunization.\n* Had any chronic use (more than 14 continuous days) of any systemic medications that affects immune function, including immunosuppressant or other immune-modifying drugs, within 6 months prior to Screening Visit unless in the opinion of the investigator, the medication would not prevent, limit, or confound the protocol-specified assessments or could compromise safety of subjects.\n* Had administration of any immunoglobulins and/or any blood products within the 3 months prior to Screening Visit.\n* Had administration of another investigational product including vaccines within 60 days or 5 half-lives (whichever is longer), prior to Screening Visit.\n* With known history of AIDS or human immunodeficiency virus (HIV) test positive.\n* History of hepatitis B virus (HBV) or hepatitis C virus (HCV) infection, through medical inquiry.\n* History of SARS, SARS-CoV-2 or middle east respiratory syndrome (MERS) infection. Suspected SARS patients should be screened for SARS antibodies.\n* Previously participated in a clinical trial involving lipid nanoparticles.\n* Are subject to exclusion periods of other clinical trials or simultaneous participation in another clinical trial.\n* Have any affiliation with the study site (e.g., are close relative of the investigator or dependent person, such as an employee or student of the study site).\n* Have a history of drug abuse or known medical, psychological, or social conditions within the past 5 years. In the opinion of the investigator, could comprise their well-being if they participate as trial subjects in the trial, or that could prevent, limit, or confound the protocol-specified assessments.\n* Have a history of narcolepsy.\n* Have history of alcohol abuse or drug addiction within 1 year prior to Screening Visit.\n* Have a history of or suspected immunosuppressive condition, acquired or congenital, as determined by medical history and/or physical examination at Screening Visit.\n* Have any abnormality or permanent body art (e.g., tattoo), that in the opinion of the investigator, would obstruct the ability to observe local reactions at the vaccination site.\n* Have had any blood loss \\>400 mL, e.g., due to donation of blood or blood products or injury, within the 28 days prior to Screening Visit or plan to donate blood or plasma during the trial, starting from Screening Visit and continuously until at least 28 days after being given the last immunization.\n* Travel or live in any country or region with a high SARS-CoV-2 infection risk (as defined at Screening Visit) within the 14 days prior to Screening Visit.\n* They plan to visit any country or region with a high SARS-CoV-2 infection risk (as defined at Screening Visit), from Screening Visit until 14 days after being given the last immunization.\n* Symptoms of COVID-19, e.g., respiratory symptoms, fever, cough, shortness of breath and breathing difficulties.\n* Have had contact with confirmed COVID-19 patients or persons tested positive for SARS-CoV-2 within the 30 days prior to Screening Visit.\n* Are vulnerable persons, e.g., soldiers, subjects in detention, contract research organization (CRO) or Fosun staff or their family members.\n\nFor the elderly group (age ≥65 and ≤85)\n\n* Baseline laboratory abnormalities with Grade ≥3 (for hematology abnormalities with Grade ≥2) during screening visits, by physical examination and eligibility screening.\n* Have had any acute illness, as determined by the investigator, with or without fever, within 72 hours prior to the prime vaccination. An acute illness which is nearly resolved with only minor residual symptoms remaining is allowable if, in the opinion of the investigator, the residual symptoms will not compromise their well-being if they participate as trial subjects in the trial, or that will not prevent, limit, or confound the protocol-specified assessments.\n* Have a known allergy, hypersensitivity, or intolerance to the planned vaccine for trial including any excipients.\n* Used to have a history of hypersensitivity or serious reactions to vaccination.\n* Received any vaccination within 4 weeks prior to Visit 1.\n* Don't agree to not be vaccinated during the trial, starting from Screening Visit and continuously until 28 days after receiving the last immunization, except emergency vaccination (e.g. rabies vaccine, tetanus vaccine).\n* Had administration of any immunoglobulins and/or any blood products within the 3 months prior to Screening Visit.\n* Had any serious or life-threatening medical condition (e.g., autoimmune disease, cardiovascular disease) within the past 5 years, which in the opinion of the investigator, could compromise their well-being if they participate as trial subjects in the trial, or that could prevent, limit, or confound the protocol-specified assessments.\n* Have any surgery planned during the trial, starting from Screening Visit and continuously until at least 90 days after the last immunization.\n* Had any chronic use (more than 14 continuous days) of any systemic medications that affects immune function, including immunosuppressant or other immune-modifying drugs, within 6 months prior to Screening Visit unless in the opinion of the investigator, the medication would not prevent, limit, or confound the protocol-specified assessments or could compromise safety of subjects.\n* Had administration of another investigational product including vaccines within 60 days or 5 half-lives (whichever is longer), prior to Screening Visit.\n* With known history of AIDS or HIV test positive.\n* History of HBV or HCV infection.\n* History of SARS, SARS-CoV-2 or MERS infection. Suspected SARS patients should be screened for SARS antibodies.\n* Previously participated in a clinical trial involving lipid nanoparticles.\n* Are subject to exclusion periods of other clinical trials or simultaneous participation in another clinical trial.\n* Have any affiliation with the study site (e.g., are close relative of the investigator or dependent person, such as an employee or student of the study site).\n* Have a history of drug abuse or known medical, psychological, or social conditions within the past 5 years. In the opinion of the investigator, could comprise their well-being if they participate as trial subjects in the trial, or that could prevent, limit, or confound the protocol-specified assessments.\n* Have a history of narcolepsy.\n* Have history of alcohol abuse or drug addiction within 1 year prior to Screening Visit.\n* Have a history of or suspected immunosuppressive condition, acquired or congenital, as determined by medical history and/or physical examination at Screening Visit.\n* Have any abnormality or permanent body art (e.g., tattoo), that in the opinion of the investigator, would obstruct the ability to observe local reactions at the vaccination site.\n* Have had any blood loss \\>400 mL, e.g., due to donation of blood or blood products or injury, within the 28 days prior to Screening Visit or plan to donate blood or plasma during the trial, starting from Screening Visit and continuously until at least 28 days after being given the last immunization.\n* Travel or live in any country or region with a high SARS-CoV-2 infection risk (as defined at Screening Visit) within the 14 days prior to Screening Visit.\n* They plan to visit any country or region with a high SARS-CoV-2 infection risk (as defined at Screening Visit), from Screening Visit until 14 days after being given the last immunization.\n* Symptoms of COVID-19, e.g., respiratory symptoms, fever, cough, shortness of breath and breathing difficulties.\n* Have had contact with confirmed COVID-19 patients or persons tested positive for SARS-CoV-2 nucleic acids or antibodies within the 30 days prior to Screening Visit.\n* Are vulnerable persons, e.g., soldiers, subjects in detention, CRO or Fosun staff or their family members.","healthyVolunteers":true,"sex":"ALL","minimumAge":"18 Years","maximumAge":"85 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"BioNTech Responsible Person","affiliation":"BioNTech SE","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"Jiangsu Provincial Center for Disease Control and Prevention","city":"Taizhou","state":"Jiangsu","zip":"210009","country":"China","geoPoint":{"lat":32.49069,"lon":119.90812}}]},"referencesModule":{"references":[{"pmid":"35771353","type":"DERIVED","citation":"Li J, Hui AM, Zhang X, Ge L, Qiu Y, Tang R, Ye H, Wang X, Lin M, Zhu Z, Zheng J, Qiu J, Lagkadinou E, Shpyro S, Ozhelvaci O, Tureci O, Khondker Z, Yin W, Shishkova Y, Jia S, Pan H, Peng F, Ma Z, Wu Z, Guo X, Shi Y, Muik A, Sahin U, Zhu L, Zhu F. Immune Persistence and Safety After SARS-CoV-2 BNT162b1 mRNA Vaccination in Chinese Adults: A Randomized, Placebo-Controlled, Double-Blind Phase 1 Trial. Adv Ther. 2022 Aug;39(8):3789-3798. doi: 10.1007/s12325-022-02206-1. Epub 2022 Jun 30."}]},"ipdSharingStatementModule":{"ipdSharing":"NO"}},"resultsSection":{"participantFlowModule":{"preAssignmentDetails":"All enrolled participants were allocated to treatment.","recruitmentDetails":"A total of 144 subjects were randomized in this phase I clinical trial, including 72 adult subjects aged 18-55 years old (including boundary value) and 72 elderly subjects aged 65-85 years old (including boundary value). The subjects received either BNT162b1 10 µg (low dose), BNT162b1 30 µg (high dose), or placebo on Day 1 and Day 22, respectively.","groups":[{"id":"FG000","title":"Low-dose 10 µg, 18-55 Years of Age","description":"BNT162b1: Intramuscular injection"},{"id":"FG001","title":"High-dose 30 µg, 18-55 Years of Age","description":"BNT162b1: Intramuscular injection"},{"id":"FG002","title":"Placebo, 18-55 Years of Age","description":"Placebo: Intramuscular injection"},{"id":"FG003","title":"Low-dose 10 µg, 65-85 Years of Age","description":"BNT162b1: Intramuscular injection"},{"id":"FG004","title":"High-dose 30 µg, 65-85 Years of Age","description":"BNT162b1: Intramuscular injection"},{"id":"FG005","title":"Placebo, 65-85 Years of Age","description":"Placebo: Intramuscular injection"}],"periods":[{"title":"Received 2 Doses","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"24"},{"groupId":"FG001","numSubjects":"24"},{"groupId":"FG002","numSubjects":"24"},{"groupId":"FG003","numSubjects":"24"},{"groupId":"FG004","numSubjects":"24"},{"groupId":"FG005","numSubjects":"24"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"24"},{"groupId":"FG001","numSubjects":"24"},{"groupId":"FG002","numSubjects":"24"},{"groupId":"FG003","numSubjects":"23"},{"groupId":"FG004","numSubjects":"23"},{"groupId":"FG005","numSubjects":"24"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"1"},{"groupId":"FG004","numSubjects":"1"},{"groupId":"FG005","numSubjects":"0"}]}],"dropWithdraws":[{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"1"},{"groupId":"FG004","numSubjects":"1"},{"groupId":"FG005","numSubjects":"0"}]}]},{"title":"Received 2 Doses and Completed Follow-up","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"24"},{"groupId":"FG001","numSubjects":"24"},{"groupId":"FG002","numSubjects":"24"},{"groupId":"FG003","numSubjects":"23"},{"groupId":"FG004","numSubjects":"23"},{"groupId":"FG005","numSubjects":"24"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"23"},{"groupId":"FG001","numSubjects":"24"},{"groupId":"FG002","numSubjects":"23"},{"groupId":"FG003","numSubjects":"22"},{"groupId":"FG004","numSubjects":"22"},{"groupId":"FG005","numSubjects":"23"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"1"},{"groupId":"FG003","numSubjects":"1"},{"groupId":"FG004","numSubjects":"1"},{"groupId":"FG005","numSubjects":"1"}]}],"dropWithdraws":[{"type":"inoculated with other COVID-19 vaccine","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"1"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"}]},{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"1"}]},{"type":"Adverse Event","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"1"},{"groupId":"FG004","numSubjects":"1"},{"groupId":"FG005","numSubjects":"0"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"Low-dose 10 µg, 18-55 Years of Age","description":"BNT162b1: Intramuscular injection"},{"id":"BG001","title":"High-dose 30 µg, 18-55 Years of Age","description":"BNT162b1: Intramuscular injection"},{"id":"BG002","title":"Placebo, 18-55 Years of Age","description":"Placebo: Intramuscular injection"},{"id":"BG003","title":"Low-dose 10 µg, 65-85 Years of Age","description":"BNT162b1: Intramuscular injection"},{"id":"BG004","title":"High-dose 30 µg, 65-85 Years of Age","description":"BNT162b1: Intramuscular injection"},{"id":"BG005","title":"Placebo, 65-85 Years of Age","description":"Placebo: Intramuscular injection"},{"id":"BG006","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"24"},{"groupId":"BG001","value":"24"},{"groupId":"BG002","value":"24"},{"groupId":"BG003","value":"24"},{"groupId":"BG004","value":"24"},{"groupId":"BG005","value":"24"},{"groupId":"BG006","value":"144"}]}],"measures":[{"title":"Age, Categorical","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"24"},{"groupId":"BG001","value":"24"},{"groupId":"BG002","value":"24"},{"groupId":"BG003","value":"24"},{"groupId":"BG004","value":"24"},{"groupId":"BG005","value":"24"},{"groupId":"BG006","value":"144"}]}],"categories":[{"title":"<=18 years","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"}]},{"title":"Between 18 and 65 years","measurements":[{"groupId":"BG000","value":"24"},{"groupId":"BG001","value":"24"},{"groupId":"BG002","value":"24"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"72"}]},{"title":">=65 years","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"24"},{"groupId":"BG004","value":"24"},{"groupId":"BG005","value":"24"},{"groupId":"BG006","value":"72"}]}]}]},{"title":"Age, Continuous","populationDescription":"Totals are presented by age group.","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"years","classes":[{"title":"Group, 18-55 years of age","denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"24"},{"groupId":"BG001","value":"24"},{"groupId":"BG002","value":"24"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"72"}]}],"categories":[{"measurements":[{"groupId":"BG000","value":"38","spread":"9.6"},{"groupId":"BG001","value":"40","spread":"9.0"},{"groupId":"BG002","value":"42","spread":"8.7"},{"groupId":"BG006","value":"40","spread":"9.2"}]}]},{"title":"Group, 65-85 years of age","denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"24"},{"groupId":"BG004","value":"24"},{"groupId":"BG005","value":"24"},{"groupId":"BG006","value":"72"}]}],"categories":[{"measurements":[{"groupId":"BG003","value":"71","spread":"5.0"},{"groupId":"BG004","value":"69","spread":"3.0"},{"groupId":"BG005","value":"71","spread":"4.4"},{"groupId":"BG006","value":"70","spread":"4.2"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"24"},{"groupId":"BG001","value":"24"},{"groupId":"BG002","value":"24"},{"groupId":"BG003","value":"24"},{"groupId":"BG004","value":"24"},{"groupId":"BG005","value":"24"},{"groupId":"BG006","value":"144"}]}],"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"12"},{"groupId":"BG001","value":"12"},{"groupId":"BG002","value":"12"},{"groupId":"BG003","value":"12"},{"groupId":"BG004","value":"12"},{"groupId":"BG005","value":"12"},{"groupId":"BG006","value":"72"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"12"},{"groupId":"BG001","value":"12"},{"groupId":"BG002","value":"12"},{"groupId":"BG003","value":"12"},{"groupId":"BG004","value":"12"},{"groupId":"BG005","value":"12"},{"groupId":"BG006","value":"72"}]}]}]},{"title":"Race/Ethnicity, Customized","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"title":"Asian","denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"24"},{"groupId":"BG001","value":"24"},{"groupId":"BG002","value":"24"},{"groupId":"BG003","value":"24"},{"groupId":"BG004","value":"24"},{"groupId":"BG005","value":"24"},{"groupId":"BG006","value":"144"}]}],"categories":[{"measurements":[{"groupId":"BG000","value":"24"},{"groupId":"BG001","value":"24"},{"groupId":"BG002","value":"24"},{"groupId":"BG003","value":"24"},{"groupId":"BG004","value":"24"},{"groupId":"BG005","value":"24"},{"groupId":"BG006","value":"144"}]}]}]},{"title":"Region of Enrollment","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"China","denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"24"},{"groupId":"BG001","value":"24"},{"groupId":"BG002","value":"24"},{"groupId":"BG003","value":"24"},{"groupId":"BG004","value":"24"},{"groupId":"BG005","value":"24"},{"groupId":"BG006","value":"144"}]}],"categories":[{"measurements":[{"groupId":"BG000","value":"24"},{"groupId":"BG001","value":"24"},{"groupId":"BG002","value":"24"},{"groupId":"BG003","value":"24"},{"groupId":"BG004","value":"24"},{"groupId":"BG005","value":"24"},{"groupId":"BG006","value":"144"}]}]}]},{"title":"Weight","populationDescription":"Totals are presented by age group.","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"kg","classes":[{"title":"Group 18-55 years of age","denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"24"},{"groupId":"BG001","value":"24"},{"groupId":"BG002","value":"24"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"72"}]}],"categories":[{"measurements":[{"groupId":"BG000","value":"69.5","spread":"12.05"},{"groupId":"BG001","value":"62.8","spread":"10.75"},{"groupId":"BG002","value":"65.7","spread":"13.26"},{"groupId":"BG006","value":"66.0","spread":"12.21"}]}]},{"title":"Group 65-85 years of age","denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"24"},{"groupId":"BG004","value":"24"},{"groupId":"BG005","value":"24"},{"groupId":"BG006","value":"72"}]}],"categories":[{"measurements":[{"groupId":"BG003","value":"61.8","spread":"9.83"},{"groupId":"BG004","value":"63.8","spread":"8.81"},{"groupId":"BG005","value":"59.0","spread":"8.36"},{"groupId":"BG006","value":"61.5","spread":"9.11"}]}]}]},{"title":"Body mass index (BMI)","populationDescription":"Totals are presented by age group.","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"kg/m^2","classes":[{"title":"Group 18-55 years of age","denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"24"},{"groupId":"BG001","value":"24"},{"groupId":"BG002","value":"24"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"72"}]}],"categories":[{"measurements":[{"groupId":"BG000","value":"24.7","spread":"3.18"},{"groupId":"BG001","value":"23.0","spread":"2.71"},{"groupId":"BG002","value":"24.3","spread":"3.43"},{"groupId":"BG006","value":"24.0","spread":"3.16"}]}]},{"title":"Group 65-85 years of age","denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"24"},{"groupId":"BG004","value":"24"},{"groupId":"BG005","value":"24"},{"groupId":"BG006","value":"72"}]}],"categories":[{"measurements":[{"groupId":"BG003","value":"23.9","spread":"2.95"},{"groupId":"BG004","value":"24.8","spread":"2.85"},{"groupId":"BG005","value":"23.5","spread":"2.45"},{"groupId":"BG006","value":"24.1","spread":"2.77"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants With Solicited Local Adverse Events (AEs) (e.g., Injection Site Pain, Redness, Induration, Swelling) Recorded up to 14 Days After Each Dose of BNT162b1 or Placebo.","description":"Solicited local AEs were collected within 7 days/14 days after each vaccination. For the grading of AEs, a 7-day period AE assessment after each dose as graded by United States (US) Food and Drug Administration (FDA) criteria along with the 14-day period AE assessment as graded by National Medical Products Administration (NMPA) criteria are used to evaluate solicited AEs. For other AEs, only the NMPA criteria is used. The \"solicited\" AEs were pre-defined and listed in the subjects' diaries. All the solicited local AEs occurred within 7 days after vaccination were related to investigational vaccine (or placebo).","populationDescription":"Safety Analysis Set including all randomized participants who receive at least one dose of the investigational vaccine/placebo and at least one safety evaluation.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","calculatePct":false,"timeFrame":"Up to 14 days following each dose administration","groups":[{"id":"OG000","title":"Low-dose 10 µg, 18-55 Years of Age","description":"BNT162b1: Intramuscular injection"},{"id":"OG001","title":"High-dose 30 µg, 18-55 Years of Age","description":"BNT162b1: Intramuscular injection"},{"id":"OG002","title":"Placebo, 18-55 Years of Age","description":"Placebo: Intramuscular injection"},{"id":"OG003","title":"Low-dose 10 µg, 65-85 Years of Age","description":"BNT162b1: Intramuscular injection"},{"id":"OG004","title":"High-dose 30 µg, 65-85 Years of Age","description":"BNT162b1: Intramuscular injection"},{"id":"OG005","title":"Placebo, 65-85 Years of Age","description":"Placebo: Intramuscular injection"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"24"},{"groupId":"OG002","value":"24"},{"groupId":"OG003","value":"24"},{"groupId":"OG004","value":"24"},{"groupId":"OG005","value":"24"}]}],"classes":[{"title":"Within 7 days after dose 1: Number of participants with solicited local AEs","categories":[{"measurements":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"24"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"13"},{"groupId":"OG004","value":"19"},{"groupId":"OG005","value":"0"}]}]},{"title":"Within 7 days after dose 2: Number of participants with solicited local AEs","categories":[{"measurements":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"20"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"15"},{"groupId":"OG004","value":"15"},{"groupId":"OG005","value":"0"}]}]},{"title":"Within 7 days after dose 1: Number of participants with solicited local AEs grade 3 (FDA criteria)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"}]}]},{"title":"Within 7 days after dose 2: Number of participants with solicited local AEs grade 3 (FDA criteria)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"}]}]},{"title":"Within 14 days after dose 1: Number of participants with solicited local AEs grade 3 (NMPA criteria)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"}]}]},{"title":"Within 14 days after dose 2: Number of participants with solicited local AEs grade 3 (NMPA criteria)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"}]}]}]},{"type":"PRIMARY","title":"Number of Participants With Solicited Systemic AEs (e.g., e.g., Nausea, Vomiting, Diarrhea, Headache, Fatigue, Myalgia, Arthralgia, Chills, Loss of Appetite, Malaise, and Fever) Recorded up to 14 Days After Each Dose of BNT162b1 or Placebo.","description":"Solicited systemic AEs were collected within 7 days/14 days after each vaccination. For the grading of AEs, a 7-day period AE assessment after each dose as graded by US FDA criteria along with the 14-day period AE assessment as graded by NMPA criteria are used to evaluate solicited AEs. For other AEs, only the NMPA criteria is used. The \"solicited\" AEs were pre-defined and listed in the subjects' diaries. Except for 1 event (myalgia) occurred in 10 µg group and 1 event (diarrhea) occurred in placebo group, all the solicited systemic AEs occurred within 7 days after vaccination were related to investigational vaccine (or placebo). All the solicited systemic AEs occurred within 14 days after vaccination were related to investigational vaccine (or placebo), except for 1 event (myalgia) occurred in placebo group and 2 events (both diarrhea; 1 event occurred in 30 µg group, 1 event occurred in placebo group).","populationDescription":"Safety Analysis Set including all randomized participants who receive at least one dose of the investigational vaccine/placebo and at least one safety evaluation.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","calculatePct":false,"timeFrame":"Up to 14 days following each dose administration","groups":[{"id":"OG000","title":"Low-dose 10 µg, 18-55 Years of Age","description":"BNT162b1: Intramuscular injection"},{"id":"OG001","title":"High-dose 30 µg, 18-55 Years of Age","description":"BNT162b1: Intramuscular injection"},{"id":"OG002","title":"Placebo, 18-55 Years of Age","description":"Placebo: Intramuscular injection"},{"id":"OG003","title":"Low-dose 10 µg, 65-85 Years of Age","description":"BNT162b1: Intramuscular injection"},{"id":"OG004","title":"High-dose 30 µg, 65-85 Years of Age","description":"BNT162b1: Intramuscular injection"},{"id":"OG005","title":"Placebo, 65-85 Years of Age","description":"Placebo: Intramuscular injection"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"24"},{"groupId":"OG002","value":"24"},{"groupId":"OG003","value":"24"},{"groupId":"OG004","value":"24"},{"groupId":"OG005","value":"24"}]}],"classes":[{"title":"Within 7 d (days) after dose 1: Number of participants with solicited systemic AEs","categories":[{"measurements":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"16"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"15"},{"groupId":"OG005","value":"2"}]}]},{"title":"Within 7 d after dose 2: Number of participants with solicited systemic AEs","categories":[{"measurements":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"21"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"7"},{"groupId":"OG004","value":"17"},{"groupId":"OG005","value":"1"}]}]},{"title":"Within 14 d after dose 1: Number of participants with solicited systemic AEs","categories":[{"measurements":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"16"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"15"},{"groupId":"OG005","value":"2"}]}]},{"title":"Within 14 d after dose 2: Number of participants with solicited systemic AEs","categories":[{"measurements":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"21"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"7"},{"groupId":"OG004","value":"17"},{"groupId":"OG005","value":"2"}]}]},{"title":"Within 7 d after dose 1: Number of participants with related solicited systemic AEs grade 3 (FDA)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"2"},{"groupId":"OG005","value":"0"}]}]},{"title":"Within 7 d after dose 2: Number of participants with related solicited systemic AEs grade 3 (FDA)","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"}]}]},{"title":"Within 14 d after dose 1: Number of participants with related solicited systemic AEs grade 3 (NMPA)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"2"},{"groupId":"OG005","value":"0"}]}]},{"title":"Within 14 d after dose 2: Number of participants with related solicited systemic AEs grade 3 (NMPA)","categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"}]}]}]},{"type":"PRIMARY","title":"Number of Participants With Unsolicited Vaccine Related AEs During the 21-day Period After Dose 1 of BNT162b1 or Placebo.","description":"AEs occurred during the 21-day period after dose 1 were also referred as \"unsolicited\" AEs. The unsolicited AEs were not pre-defined in the subjects' diaries.","populationDescription":"Safety Analysis Set including all randomized participants who receive at least one dose of the investigational vaccine/placebo and at least one safety evaluation.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"participants","timeFrame":"21-day period after dose 1 vaccination","groups":[{"id":"OG000","title":"Low-dose 10 µg, 18-55 Years of Age","description":"BNT162b1: Intramuscular injection"},{"id":"OG001","title":"High-dose 30 µg, 18-55 Years of Age","description":"BNT162b1: Intramuscular injection"},{"id":"OG002","title":"Placebo, 18-55 Years of Age","description":"Placebo: Intramuscular injection"},{"id":"OG003","title":"Low-dose 10 µg, 65-85 Years of Age","description":"BNT162b1: Intramuscular injection"},{"id":"OG004","title":"High-dose 30 µg, 65-85 Years of Age","description":"BNT162b1: Intramuscular injection"},{"id":"OG005","title":"Placebo, 65-85 Years of Age","description":"Placebo: Intramuscular injection"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"24"},{"groupId":"OG002","value":"24"},{"groupId":"OG003","value":"24"},{"groupId":"OG004","value":"24"},{"groupId":"OG005","value":"24"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"5"},{"groupId":"OG005","value":"2"}]}]}]},{"type":"PRIMARY","title":"Number of Participants With Unsolicited Vaccine Related AEs During the 28-day Period After Dose 2 of BNT162b1 or Placebo.","description":"AEs occurred during the 28-day period after dose 2 were also referred as \"unsolicited\" AEs. The unsolicited AEs were not pre-defined in the subjects' diaries.","populationDescription":"Safety Analysis Set including all randomized participants who receive at least one dose of the investigational vaccine/placebo and at least one safety evaluation.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"participants","timeFrame":"28-day period after dose 2 vaccination","groups":[{"id":"OG000","title":"Low-dose 10 µg, 18-55 Years of Age","description":"BNT162b1: Intramuscular injection"},{"id":"OG001","title":"High-dose 30 µg, 18-55 Years of Age","description":"BNT162b1: Intramuscular injection"},{"id":"OG002","title":"Placebo, 18-55 Years of Age","description":"Placebo: Intramuscular injection"},{"id":"OG003","title":"Low-dose 10 µg, 65-85 Years of Age","description":"BNT162b1: Intramuscular injection"},{"id":"OG004","title":"High-dose 30 µg, 65-85 Years of Age","description":"BNT162b1: Intramuscular injection"},{"id":"OG005","title":"Placebo, 65-85 Years of Age","description":"Placebo: Intramuscular injection"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"24"},{"groupId":"OG002","value":"24"},{"groupId":"OG003","value":"24"},{"groupId":"OG004","value":"24"},{"groupId":"OG005","value":"24"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"7"},{"groupId":"OG005","value":"0"}]}]}]},{"type":"SECONDARY","title":"The Number of Participants Experiencing Treatment Emergent Serious Adverse Events (TESAEs)","populationDescription":"Safety Analysis Set including all randomized subjects who receive at least one dose of the investigational vaccine/placebo and at least one safety evaluation.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"participants","timeFrame":"From Dose 1 up to Month 12","groups":[{"id":"OG000","title":"Low-dose 10 µg, 18-55 Years of Age","description":"BNT162b1: Intramuscular injection"},{"id":"OG001","title":"High-dose 30 µg, 18-55 Years of Age","description":"BNT162b1: Intramuscular injection"},{"id":"OG002","title":"Placebo, 18-55 Years of Age","description":"Placebo: Intramuscular injection"},{"id":"OG003","title":"Low-dose 10 µg, 65-85 Years of Age","description":"BNT162b1: Intramuscular injection"},{"id":"OG004","title":"High-dose 30 µg, 65-85 Years of Age","description":"BNT162b1: Intramuscular injection"},{"id":"OG005","title":"Placebo, 65-85 Years of Age","description":"Placebo: Intramuscular injection"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"24"},{"groupId":"OG002","value":"24"},{"groupId":"OG003","value":"24"},{"groupId":"OG004","value":"24"},{"groupId":"OG005","value":"24"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"}]}]}]},{"type":"SECONDARY","title":"The Number of Participants Experiencing Related TEAEs","description":"\"Related\" implies the relationship between AE and vaccine is one of \"Possibly related\", \"Probably related\" and \"Definitely related\".","populationDescription":"Safety Analysis Set including all randomized subjects who receive at least one dose of the investigational vaccine/placebo and at least one safety evaluation.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"participants","timeFrame":"From Dose 1 up to Month 12","groups":[{"id":"OG000","title":"Low-dose 10 µg, 18-55 Years of Age","description":"BNT162b1: Intramuscular injection"},{"id":"OG001","title":"High-dose 30 µg, 18-55 Years of Age","description":"BNT162b1: Intramuscular injection"},{"id":"OG002","title":"Placebo, 18-55 Years of Age","description":"Placebo: Intramuscular injection"},{"id":"OG003","title":"Low-dose 10 µg, 65-85 Years of Age","description":"BNT162b1: Intramuscular injection"},{"id":"OG004","title":"High-dose 30 µg, 65-85 Years of Age","description":"BNT162b1: Intramuscular injection"},{"id":"OG005","title":"Placebo, 65-85 Years of Age","description":"Placebo: Intramuscular injection"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"24"},{"groupId":"OG002","value":"24"},{"groupId":"OG003","value":"24"},{"groupId":"OG004","value":"24"},{"groupId":"OG005","value":"24"}]}],"classes":[{"title":"Number of Participants with related TEAEs after dose 1","categories":[{"measurements":[{"groupId":"OG000","value":"22"},{"groupId":"OG001","value":"24"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"16"},{"groupId":"OG004","value":"21"},{"groupId":"OG005","value":"4"}]}]},{"title":"Number of Participants with related TEAEs after dose 2","categories":[{"measurements":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"22"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"18"},{"groupId":"OG004","value":"21"},{"groupId":"OG005","value":"0"}]}]}]},{"type":"SECONDARY","title":"The Number of Participants Experiencing Clinically Significant (CS) Abnormal Markers of Hematology, Blood Chemistry and Urine Analysis","description":"Results for CS results are displayed by abnormal parameter. Abnormal test results assessed not clinical significant are not presented. Participants with more than one 'CS' parameter are counted for each parameter separately and therefore included multiple times.","populationDescription":"The safety analysis set included all randomized subjects who receive at least one dose of the investigational vaccine/placebo and have at least one safety evaluation.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Hour 24 and Day 7 after dose 1 and Day 7 after dose 2","groups":[{"id":"OG000","title":"Low-dose 10 µg, 18-55 Years of Age","description":"BNT162b1: Intramuscular injection"},{"id":"OG001","title":"High-dose 30 µg, 18-55 Years of Age","description":"BNT162b1: Intramuscular injection"},{"id":"OG002","title":"Placebo, 18-55 Years of Age","description":"Placebo: Intramuscular injection"},{"id":"OG003","title":"Low-dose 10 µg, 65-85 Years of Age","description":"BNT162b1: Intramuscular injection"},{"id":"OG004","title":"High-dose 30 µg, 65-85 Years of Age","description":"BNT162b1: Intramuscular injection"},{"id":"OG005","title":"Placebo, 65-85 Years of Age","description":"Placebo: Intramuscular injection"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"24"},{"groupId":"OG002","value":"24"},{"groupId":"OG003","value":"24"},{"groupId":"OG004","value":"24"},{"groupId":"OG005","value":"24"}]}],"classes":[{"title":"CS abnormal blood chemistry parameter - increased total bilirubin - 24 hours after dose 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"24"},{"groupId":"OG002","value":"24"},{"groupId":"OG003","value":"24"},{"groupId":"OG004","value":"24"},{"groupId":"OG005","value":"24"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"}]}]},{"title":"CS abnormal blood chemistry parameter - increased total bilirubin - Day 7 after dose 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"24"},{"groupId":"OG002","value":"24"},{"groupId":"OG003","value":"24"},{"groupId":"OG004","value":"24"},{"groupId":"OG005","value":"24"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"}]}]},{"title":"CS abnormal blood chemistry parameter - increased total bilirubin - Day 7 after dose 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"24"},{"groupId":"OG002","value":"24"},{"groupId":"OG003","value":"23"},{"groupId":"OG004","value":"23"},{"groupId":"OG005","value":"24"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"}]}]},{"title":"CS abnormal urine routine test results - elevated leucocyte (microscopic) - 24 hours after dose 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"24"},{"groupId":"OG002","value":"24"},{"groupId":"OG003","value":"24"},{"groupId":"OG004","value":"24"},{"groupId":"OG005","value":"24"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"1"}]}]},{"title":"CS abnormal urine routine test results - elevated leucocyte (microscopic) - Day 7 after dose 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"24"},{"groupId":"OG002","value":"24"},{"groupId":"OG003","value":"24"},{"groupId":"OG004","value":"24"},{"groupId":"OG005","value":"24"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"}]}]},{"title":"CS abnormal urine routine test results - elevated leucocyte (microscopic) - Day 7 after dose 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"24"},{"groupId":"OG002","value":"24"},{"groupId":"OG003","value":"23"},{"groupId":"OG004","value":"22"},{"groupId":"OG005","value":"24"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"}]}]},{"title":"CS abnormal urine routine test results - bacteria (microscopic) - 24 hours after dose 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"24"},{"groupId":"OG002","value":"24"},{"groupId":"OG003","value":"24"},{"groupId":"OG004","value":"24"},{"groupId":"OG005","value":"24"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"1"}]}]},{"title":"CS abnormal urine routine test results - bacteria (microscopic) - Day 7 after dose 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"24"},{"groupId":"OG002","value":"24"},{"groupId":"OG003","value":"24"},{"groupId":"OG004","value":"24"},{"groupId":"OG005","value":"24"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"1"}]}]},{"title":"CS abnormal urine routine test results - bacteria (microscopic) - Day 7 after dose 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"24"},{"groupId":"OG002","value":"24"},{"groupId":"OG003","value":"23"},{"groupId":"OG004","value":"22"},{"groupId":"OG005","value":"24"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"}]}]},{"title":"CS abnormal urine routine test results - red blood cells (microscopic) - 24 hours after dose 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"24"},{"groupId":"OG002","value":"24"},{"groupId":"OG003","value":"24"},{"groupId":"OG004","value":"24"},{"groupId":"OG005","value":"24"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"}]}]},{"title":"CS abnormal urine routine test results - red blood cells (microscopic) - Day 7 after dose 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"24"},{"groupId":"OG002","value":"24"},{"groupId":"OG003","value":"24"},{"groupId":"OG004","value":"24"},{"groupId":"OG005","value":"24"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"}]}]},{"title":"CS abnormal urine routine test results - red blood cells (microscopic) - Day 7 after dose 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"24"},{"groupId":"OG002","value":"24"},{"groupId":"OG003","value":"23"},{"groupId":"OG004","value":"22"},{"groupId":"OG005","value":"24"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"}]}]},{"title":"CS abnormal urine routine test results - glucose - 24 hours after dose 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"24"},{"groupId":"OG002","value":"24"},{"groupId":"OG003","value":"24"},{"groupId":"OG004","value":"24"},{"groupId":"OG005","value":"24"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"}]}]},{"title":"CS abnormal urine routine test results - glucose - Day 7 after dose 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"24"},{"groupId":"OG002","value":"24"},{"groupId":"OG003","value":"24"},{"groupId":"OG004","value":"24"},{"groupId":"OG005","value":"24"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"0"}]}]},{"title":"CS abnormal urine routine test results - glucose - Day 7 after dose 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"24"},{"groupId":"OG002","value":"24"},{"groupId":"OG003","value":"23"},{"groupId":"OG004","value":"22"},{"groupId":"OG005","value":"24"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"}]}]},{"title":"CS abnormal urine routine test results - ketone - 24 hours after dose 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"24"},{"groupId":"OG002","value":"24"},{"groupId":"OG003","value":"24"},{"groupId":"OG004","value":"24"},{"groupId":"OG005","value":"24"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"}]}]},{"title":"CS abnormal urine routine test results - ketone - Day 7 after dose 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"24"},{"groupId":"OG002","value":"24"},{"groupId":"OG003","value":"24"},{"groupId":"OG004","value":"24"},{"groupId":"OG005","value":"24"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"0"}]}]},{"title":"CS abnormal urine routine test results - ketone - Day 7 after dose 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"24"},{"groupId":"OG002","value":"24"},{"groupId":"OG003","value":"23"},{"groupId":"OG004","value":"22"},{"groupId":"OG005","value":"24"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"}]}]},{"title":"CS abnormal urine routine test results - blood - 24 hours after dose 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"24"},{"groupId":"OG002","value":"24"},{"groupId":"OG003","value":"24"},{"groupId":"OG004","value":"24"},{"groupId":"OG005","value":"24"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"}]}]},{"title":"CS abnormal urine routine test results - blood - Day 7 after dose 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"24"},{"groupId":"OG002","value":"24"},{"groupId":"OG003","value":"24"},{"groupId":"OG004","value":"24"},{"groupId":"OG005","value":"24"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"}]}]},{"title":"CS abnormal urine routine test results - blood - Day 7 after dose 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"24"},{"groupId":"OG002","value":"24"},{"groupId":"OG003","value":"23"},{"groupId":"OG004","value":"22"},{"groupId":"OG005","value":"24"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"}]}]},{"title":"CS abnormal hematology parameter - hemoglobin - 24 hours after dose 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"24"},{"groupId":"OG002","value":"24"},{"groupId":"OG003","value":"24"},{"groupId":"OG004","value":"24"},{"groupId":"OG005","value":"24"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"}]}]},{"title":"CS abnormal hematology parameter - hemoglobin - Day 7 after dose 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"24"},{"groupId":"OG002","value":"24"},{"groupId":"OG003","value":"24"},{"groupId":"OG004","value":"24"},{"groupId":"OG005","value":"24"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"}]}]},{"title":"CS abnormal hematology parameter - hemoglobin - Day 7 after dose 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"24"},{"groupId":"OG002","value":"24"},{"groupId":"OG003","value":"23"},{"groupId":"OG004","value":"23"},{"groupId":"OG005","value":"24"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"}]}]},{"title":"CS abnormal hematology parameter - hematocrit - 24 hours after dose 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"24"},{"groupId":"OG002","value":"24"},{"groupId":"OG003","value":"24"},{"groupId":"OG004","value":"24"},{"groupId":"OG005","value":"24"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"}]}]},{"title":"CS abnormal hematology parameter - hematocrit - Day 7 after dose 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"24"},{"groupId":"OG002","value":"24"},{"groupId":"OG003","value":"24"},{"groupId":"OG004","value":"24"},{"groupId":"OG005","value":"24"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"}]}]},{"title":"CS abnormal hematology parameter - hematocrit - Day 7 after dose 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"24"},{"groupId":"OG002","value":"24"},{"groupId":"OG003","value":"23"},{"groupId":"OG004","value":"23"},{"groupId":"OG005","value":"24"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"}]}]},{"title":"CS abnormal hematology parameter - lymphocyte - 24 hours after dose 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"24"},{"groupId":"OG002","value":"24"},{"groupId":"OG003","value":"24"},{"groupId":"OG004","value":"24"},{"groupId":"OG005","value":"24"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"}]}]},{"title":"CS abnormal hematology parameter - lymphocyte - Day 7 after dose 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"24"},{"groupId":"OG002","value":"24"},{"groupId":"OG003","value":"24"},{"groupId":"OG004","value":"24"},{"groupId":"OG005","value":"24"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"1"}]}]},{"title":"CS abnormal hematology parameter - lymphocyte - Day 7 after dose 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"24"},{"groupId":"OG002","value":"24"},{"groupId":"OG003","value":"23"},{"groupId":"OG004","value":"22"},{"groupId":"OG005","value":"24"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"}]}]},{"title":"CS abnormal hematology parameter - platelet count - 24 hours after dose 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"24"},{"groupId":"OG002","value":"24"},{"groupId":"OG003","value":"24"},{"groupId":"OG004","value":"24"},{"groupId":"OG005","value":"24"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"2"},{"groupId":"OG005","value":"0"}]}]},{"title":"CS abnormal hematology parameter - platelet count - Day 7 after dose 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"24"},{"groupId":"OG002","value":"24"},{"groupId":"OG003","value":"24"},{"groupId":"OG004","value":"24"},{"groupId":"OG005","value":"24"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"}]}]},{"title":"CS abnormal hematology parameter - platelet count - Day 7 after dose 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"24"},{"groupId":"OG002","value":"24"},{"groupId":"OG003","value":"23"},{"groupId":"OG004","value":"23"},{"groupId":"OG005","value":"24"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"}]}]}]},{"type":"SECONDARY","title":"Geometric Mean Titer (GMT) of Anti-S1 IgG Antibody","description":"At Day 7, Day 21 after dose 1, at Day 7, Day 21 after dose 2, and at Month 3, 6 and 12 after dose 1.","populationDescription":"Per Protocol Set (PPS) - all subjects in the Total Vaccinated Cohort (TVC) who had no major protocol violations and completed dose 2. The TVC included all randomized subjects who had received at least one dose of the investigational vaccine/placebo and could provide with effective baseline.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"titer","timeFrame":"Up to 12 months following first dose","groups":[{"id":"OG000","title":"Low-dose 10 µg, 18-55 Years of Age","description":"BNT162b1: Intramuscular injection"},{"id":"OG001","title":"High-dose 30 µg, 18-55 Years of Age","description":"BNT162b1: Intramuscular injection"},{"id":"OG002","title":"Placebo, 18-55 Years of Age","description":"Placebo: Intramuscular injection"},{"id":"OG003","title":"Low-dose 10 µg, 65-85 Years of Age","description":"BNT162b1: Intramuscular injection"},{"id":"OG004","title":"High-dose 30 µg, 65-85 Years of Age","description":"BNT162b1: Intramuscular injection"},{"id":"OG005","title":"Placebo, 65-85 Years of Age","description":"Placebo: Intramuscular injection"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"24"},{"groupId":"OG002","value":"24"},{"groupId":"OG003","value":"23"},{"groupId":"OG004","value":"23"},{"groupId":"OG005","value":"24"}]}],"classes":[{"title":"7 days after dose 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"24"},{"groupId":"OG002","value":"24"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"53.320","lowerLimit":"46.680","upperLimit":"60.905"},{"groupId":"OG001","value":"59.220","lowerLimit":"41.728","upperLimit":"84.046"},{"groupId":"OG002","value":"52.841","lowerLimit":"47.132","upperLimit":"59.242"}]}]},{"title":"21 days after dose 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"24"},{"groupId":"OG002","value":"24"},{"groupId":"OG003","value":"23"},{"groupId":"OG004","value":"23"},{"groupId":"OG005","value":"24"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"4193.710","lowerLimit":"2664.050","upperLimit":"6601.681"},{"groupId":"OG001","value":"4531.416","lowerLimit":"3029.130","upperLimit":"6778.757"},{"groupId":"OG002","value":"52.594","lowerLimit":"47.369","upperLimit":"58.395"},{"groupId":"OG003","value":"859.646","lowerLimit":"467.549","upperLimit":"1580.564"},{"groupId":"OG004","value":"2872.861","lowerLimit":"1685.729","upperLimit":"4896.002"},{"groupId":"OG005","value":"62.239","lowerLimit":"47.583","upperLimit":"81.410"}]}]},{"title":"7 days after dose 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"24"},{"groupId":"OG002","value":"24"},{"groupId":"OG003","value":"23"},{"groupId":"OG004","value":"23"},{"groupId":"OG005","value":"24"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"26548.853","lowerLimit":"18381.541","upperLimit":"38345.078"},{"groupId":"OG001","value":"41530.498","lowerLimit":"33984.171","upperLimit":"50752.518"},{"groupId":"OG002","value":"52.578","lowerLimit":"47.384","upperLimit":"58.341"},{"groupId":"OG003","value":"5271.560","lowerLimit":"2484.575","upperLimit":"11184.748"},{"groupId":"OG004","value":"23447.197","lowerLimit":"15268.301","upperLimit":"36007.348"},{"groupId":"OG005","value":"62.658","lowerLimit":"47.633","upperLimit":"82.423"}]}]},{"title":"21 days after dose 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"24"},{"groupId":"OG002","value":"24"},{"groupId":"OG003","value":"23"},{"groupId":"OG004","value":"23"},{"groupId":"OG005","value":"24"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"46810.469","lowerLimit":"41673.251","upperLimit":"52580.970"},{"groupId":"OG001","value":"49773.381","lowerLimit":"46947.113","upperLimit":"52769.794"},{"groupId":"OG002","value":"50.000","lowerLimit":"50.000","upperLimit":"50.000"},{"groupId":"OG003","value":"40942.862","lowerLimit":"33177.420","upperLimit":"50525.869"},{"groupId":"OG004","value":"44159.581","lowerLimit":"37139.275","upperLimit":"52506.910"},{"groupId":"OG005","value":"61.008","lowerLimit":"45.725","upperLimit":"81.399"}]}]},{"title":"Month 3 after dose 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"24"},{"groupId":"OG002","value":"24"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"27143.015","lowerLimit":"21023.440","upperLimit":"35043.897"},{"groupId":"OG001","value":"31584.450","lowerLimit":"26378.938","upperLimit":"37817.196"},{"groupId":"OG002","value":"50.000","lowerLimit":"50.000","upperLimit":"50.000"}]}]},{"title":"Month 6 after dose 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"24"},{"groupId":"OG002","value":"22"},{"groupId":"OG003","value":"23"},{"groupId":"OG004","value":"23"},{"groupId":"OG005","value":"23"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"4169.448","lowerLimit":"2978.898","upperLimit":"5835.815"},{"groupId":"OG001","value":"5693.082","lowerLimit":"4412.125","upperLimit":"7345.934"},{"groupId":"OG002","value":"55.088","lowerLimit":"47.853","upperLimit":"63.417"},{"groupId":"OG003","value":"2223.699","lowerLimit":"1565.907","upperLimit":"3157.811"},{"groupId":"OG004","value":"4970.376","lowerLimit":"3625.506","upperLimit":"6814.121"},{"groupId":"OG005","value":"60.931","lowerLimit":"45.837","upperLimit":"80.995"}]}]},{"title":"Month 12 after dose 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"23"},{"groupId":"OG001","value":"24"},{"groupId":"OG002","value":"23"},{"groupId":"OG003","value":"22"},{"groupId":"OG004","value":"22"},{"groupId":"OG005","value":"23"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2002.152","lowerLimit":"1389.905","upperLimit":"2884.090"},{"groupId":"OG001","value":"2792.605","lowerLimit":"2118.269","upperLimit":"3681.610"},{"groupId":"OG002","value":"50.000","lowerLimit":"50.000","upperLimit":"50.000"},{"groupId":"OG003","value":"1104.860","lowerLimit":"698.932","upperLimit":"1746.542"},{"groupId":"OG004","value":"2847.010","lowerLimit":"1887.353","upperLimit":"4294.621"},{"groupId":"OG005","value":"53.105","lowerLimit":"46.867","upperLimit":"60.174"}]}]}]},{"type":"SECONDARY","title":"GMT of Anti-receptor Binding Domain (RBD) Immunoglobulin G (IgG) Antibody","description":"At Day 7, Day 21 after dose 1, at Day 7, Day 21 after dose 2, and at Month 3, 6 and 12 after dose 1.","populationDescription":"Per Protocol Set (PPS) - all subjects in the Total Vaccinated Cohort (TVC) who had no major protocol violations and completed dose 2. The TVC included all randomized subjects who had received at least one dose of the investigational vaccine/placebo and could provide with effective baseline.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"titer","timeFrame":"Up to 12 months following first dose","groups":[{"id":"OG000","title":"Low-dose 10 µg, 18-55 Years of Age","description":"BNT162b1: Intramuscular injection"},{"id":"OG001","title":"High-dose 30 µg, 18-55 Years of Age","description":"BNT162b1: Intramuscular injection"},{"id":"OG002","title":"Placebo, 18-55 Years of Age","description":"Placebo: Intramuscular injection"},{"id":"OG003","title":"Low-dose 10 µg, 65-85 Years of Age","description":"BNT162b1: Intramuscular injection"},{"id":"OG004","title":"High-dose 30 µg, 65-85 Years of Age","description":"BNT162b1: Intramuscular injection"},{"id":"OG005","title":"Placebo, 65-85 Years of Age","description":"Placebo: Intramuscular injection"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"24"},{"groupId":"OG002","value":"24"},{"groupId":"OG003","value":"23"},{"groupId":"OG004","value":"23"},{"groupId":"OG005","value":"24"}]}],"classes":[{"title":"7 days after dose 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"24"},{"groupId":"OG002","value":"24"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"50.000","lowerLimit":"50.000","upperLimit":"50.000"},{"groupId":"OG001","value":"52.903","lowerLimit":"47.074","upperLimit":"59.453"},{"groupId":"OG002","value":"56.644","lowerLimit":"48.999","upperLimit":"65.482"}]}]},{"title":"21 days after dose 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"24"},{"groupId":"OG002","value":"24"},{"groupId":"OG003","value":"23"},{"groupId":"OG004","value":"23"},{"groupId":"OG005","value":"24"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"13095.167","lowerLimit":"8395.009","upperLimit":"20426.827"},{"groupId":"OG001","value":"13046.378","lowerLimit":"8950.882","upperLimit":"19015.777"},{"groupId":"OG002","value":"56.699","lowerLimit":"49.052","upperLimit":"65.537"},{"groupId":"OG003","value":"3040.808","lowerLimit":"1569.768","upperLimit":"5890.369"},{"groupId":"OG004","value":"10370.854","lowerLimit":"5955.358","upperLimit":"18060.142"},{"groupId":"OG005","value":"74.476","lowerLimit":"55.679","upperLimit":"99.618"}]}]},{"title":"7 days after dose 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"24"},{"groupId":"OG002","value":"24"},{"groupId":"OG003","value":"23"},{"groupId":"OG004","value":"23"},{"groupId":"OG005","value":"24"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"38314.550","lowerLimit":"30173.509","upperLimit":"48652.107"},{"groupId":"OG001","value":"47324.691","lowerLimit":"43213.653","upperLimit":"51826.824"},{"groupId":"OG002","value":"57.377","lowerLimit":"49.028","upperLimit":"67.146"},{"groupId":"OG003","value":"10748.566","lowerLimit":"5512.317","upperLimit":"20958.821"},{"groupId":"OG004","value":"38256.083","lowerLimit":"30078.753","upperLimit":"48656.534"},{"groupId":"OG005","value":"75.817","lowerLimit":"55.962","upperLimit":"102.715"}]}]},{"title":"21 days after dose 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"24"},{"groupId":"OG002","value":"24"},{"groupId":"OG003","value":"23"},{"groupId":"OG004","value":"23"},{"groupId":"OG005","value":"24"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"49710.291","lowerLimit":"46764.743","upperLimit":"52841.369"},{"groupId":"OG001","value":"51200.000","lowerLimit":"51200.000","upperLimit":"51200.000"},{"groupId":"OG002","value":"60.605","lowerLimit":"48.454","upperLimit":"75.804"},{"groupId":"OG003","value":"46980.825","lowerLimit":"42021.855","upperLimit":"52525.000"},{"groupId":"OG004","value":"50977.162","lowerLimit":"50528.938","upperLimit":"51429.363"},{"groupId":"OG005","value":"65.756","lowerLimit":"53.237","upperLimit":"81.218"}]}]},{"title":"Month 3 after dose 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"24"},{"groupId":"OG002","value":"24"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"40236.195","lowerLimit":"32999.573","upperLimit":"49059.768"},{"groupId":"OG001","value":"43050.715","lowerLimit":"38767.819","upperLimit":"47806.766"},{"groupId":"OG002","value":"60.439","lowerLimit":"49.911","upperLimit":"73.188"}]}]},{"title":"Month 6 after dose 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"24"},{"groupId":"OG002","value":"22"},{"groupId":"OG003","value":"23"},{"groupId":"OG004","value":"23"},{"groupId":"OG005","value":"23"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"8249.604","lowerLimit":"6186.091","upperLimit":"11001.449"},{"groupId":"OG001","value":"9608.488","lowerLimit":"7410.049","upperLimit":"12459.167"},{"groupId":"OG002","value":"61.768","lowerLimit":"50.272","upperLimit":"75.894"},{"groupId":"OG003","value":"4114.353","lowerLimit":"2716.614","upperLimit":"6231.250"},{"groupId":"OG004","value":"7187.827","lowerLimit":"5138.636","upperLimit":"10054.194"},{"groupId":"OG005","value":"54.780","lowerLimit":"48.060","upperLimit":"62.439"}]}]},{"title":"Month 12 after dose 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"23"},{"groupId":"OG001","value":"24"},{"groupId":"OG002","value":"23"},{"groupId":"OG003","value":"22"},{"groupId":"OG004","value":"22"},{"groupId":"OG005","value":"23"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2324.072","lowerLimit":"1677.862","upperLimit":"3219.163"},{"groupId":"OG001","value":"2804.882","lowerLimit":"2191.409","upperLimit":"3590.094"},{"groupId":"OG002","value":"56.083","lowerLimit":"47.501","upperLimit":"66.216"},{"groupId":"OG003","value":"1536.143","lowerLimit":"921.738","upperLimit":"2560.094"},{"groupId":"OG004","value":"2768.366","lowerLimit":"1880.754","upperLimit":"4074.881"},{"groupId":"OG005","value":"63.175","lowerLimit":"50.876","upperLimit":"78.447"}]}]}]},{"type":"SECONDARY","title":"GMT of SARS-CoV-2 Neutralizing Antibody (Including True Virus-based SARS-CoV-2 Neutralizing Test)","description":"At Day 7, Day 21 after first dose, at Day 7, Day 21 after second dose, and at Month 3, 6, and 12 after first dose.","populationDescription":"Per Protocol Set (PPS) - all subjects in the Total Vaccinated Cohort (TVC) who had no major protocol violations and completed dose 2. The TVC included all randomized subjects who had received at least one dose of the investigational vaccine/placebo and could provide with effective baseline.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"titer","timeFrame":"Up to 12 months following first dose","groups":[{"id":"OG000","title":"Low-dose 10 µg, 18-55 Years of Age","description":"BNT162b1: Intramuscular injection"},{"id":"OG001","title":"High-dose 30 µg, 18-55 Years of Age","description":"BNT162b1: Intramuscular injection"},{"id":"OG002","title":"Placebo, 18-55 Years of Age","description":"Placebo: Intramuscular injection"},{"id":"OG003","title":"Low-dose 10 µg, 65-85 Years of Age","description":"BNT162b1: Intramuscular injection"},{"id":"OG004","title":"High-dose 30 µg, 65-85 Years of Age","description":"BNT162b1: Intramuscular injection"},{"id":"OG005","title":"Placebo, 65-85 Years of Age","description":"Placebo: Intramuscular injection"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"24"},{"groupId":"OG002","value":"24"},{"groupId":"OG003","value":"23"},{"groupId":"OG004","value":"23"},{"groupId":"OG005","value":"24"}]}],"classes":[{"title":"7 days after dose 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"24"},{"groupId":"OG002","value":"24"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5.000","lowerLimit":"5.000","upperLimit":"5.000"},{"groupId":"OG001","value":"5.000","lowerLimit":"5.000","upperLimit":"5.000"},{"groupId":"OG002","value":"5.000","lowerLimit":"5.000","upperLimit":"5.000"}]}]},{"title":"21 days after dose 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"24"},{"groupId":"OG002","value":"24"},{"groupId":"OG003","value":"23"},{"groupId":"OG004","value":"23"},{"groupId":"OG005","value":"24"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"18.877","lowerLimit":"10.586","upperLimit":"33.664"},{"groupId":"OG001","value":"14.557","lowerLimit":"9.712","upperLimit":"21.817"},{"groupId":"OG002","value":"5.000","lowerLimit":"5.000","upperLimit":"5.000"},{"groupId":"OG003","value":"6.965","lowerLimit":"5.037","upperLimit":"9.633"},{"groupId":"OG004","value":"10.946","lowerLimit":"7.213","upperLimit":"16.612"},{"groupId":"OG005","value":"5.000","lowerLimit":"5.000","upperLimit":"5.000"}]}]},{"title":"7 days after dose 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"24"},{"groupId":"OG002","value":"24"},{"groupId":"OG003","value":"23"},{"groupId":"OG004","value":"23"},{"groupId":"OG005","value":"24"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"56.569","lowerLimit":"31.503","upperLimit":"101.579"},{"groupId":"OG001","value":"119.865","lowerLimit":"81.547","upperLimit":"176.187"},{"groupId":"OG002","value":"5.000","lowerLimit":"5.000","upperLimit":"5.000"},{"groupId":"OG003","value":"14.357","lowerLimit":"8.689","upperLimit":"23.721"},{"groupId":"OG004","value":"49.394","lowerLimit":"26.334","upperLimit":"92.647"},{"groupId":"OG005","value":"5.000","lowerLimit":"5.000","upperLimit":"5.000"}]}]},{"title":"21 days after dose 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"24"},{"groupId":"OG002","value":"24"},{"groupId":"OG003","value":"23"},{"groupId":"OG004","value":"23"},{"groupId":"OG005","value":"24"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"232.905","lowerLimit":"151.299","upperLimit":"358.525"},{"groupId":"OG001","value":"253.984","lowerLimit":"184.601","upperLimit":"349.445"},{"groupId":"OG002","value":"5.000","lowerLimit":"5.000","upperLimit":"5.000"},{"groupId":"OG003","value":"80.000","lowerLimit":"49.173","upperLimit":"130.153"},{"groupId":"OG004","value":"160.000","lowerLimit":"96.736","upperLimit":"264.637"},{"groupId":"OG005","value":"5.000","lowerLimit":"5.000","upperLimit":"5.000"}]}]},{"title":"Month 3 after dose 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"24"},{"groupId":"OG002","value":"24"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"54.958","lowerLimit":"38.115","upperLimit":"79.245"},{"groupId":"OG001","value":"87.241","lowerLimit":"64.445","upperLimit":"118.099"},{"groupId":"OG002","value":"5.000","lowerLimit":"5.000","upperLimit":"5.000"}]}]},{"title":"Month 6 after dose 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"24"},{"groupId":"OG002","value":"22"},{"groupId":"OG003","value":"23"},{"groupId":"OG004","value":"23"},{"groupId":"OG005","value":"23"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"16.339","lowerLimit":"11.274","upperLimit":"23.679"},{"groupId":"OG001","value":"27.479","lowerLimit":"20.383","upperLimit":"37.046"},{"groupId":"OG002","value":"5.000","lowerLimit":"5.000","upperLimit":"5.000"},{"groupId":"OG003","value":"10.000","lowerLimit":"7.219","upperLimit":"13.852"},{"groupId":"OG004","value":"20.612","lowerLimit":"13.303","upperLimit":"31.937"},{"groupId":"OG005","value":"5.000","lowerLimit":"5.000","upperLimit":"5.000"}]}]},{"title":"Month 12 after dose 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"23"},{"groupId":"OG001","value":"24"},{"groupId":"OG002","value":"23"},{"groupId":"OG003","value":"22"},{"groupId":"OG004","value":"22"},{"groupId":"OG005","value":"23"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"7.858","lowerLimit":"6.027","upperLimit":"10.244"},{"groupId":"OG001","value":"11.892","lowerLimit":"8.903","upperLimit":"15.885"},{"groupId":"OG002","value":"5.000","lowerLimit":"5.000","upperLimit":"5.000"},{"groupId":"OG003","value":"6.040","lowerLimit":"4.976","upperLimit":"7.333"},{"groupId":"OG004","value":"12.081","lowerLimit":"8.154","upperLimit":"17.899"},{"groupId":"OG005","value":"5.000","lowerLimit":"5.000","upperLimit":"5.000"}]}]}]},{"type":"SECONDARY","title":"Fold Increase in Antibody Anti-S1 IgG Antibody Titers, as Compared to Baseline","description":"At Day 7, Day 21 after dose 1, at Day 7, Day 21 after dose 2, and at Month 3, 6, and 12 after dose 1.","populationDescription":"Per Protocol Set (PPS) - all subjects in the Total Vaccinated Cohort (TVC) who had no major protocol violations and completed dose 2. The TVC included all randomized subjects who had received at least one dose of the investigational vaccine/placebo and could provide with effective baseline.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"fold rise","timeFrame":"Up to 12 months following the first dose","groups":[{"id":"OG000","title":"Low-dose 10 µg, 18-55 Years of Age","description":"BNT162b1: Intramuscular injection"},{"id":"OG001","title":"High-dose 30 µg, 18-55 Years of Age","description":"BNT162b1: Intramuscular injection"},{"id":"OG002","title":"Placebo, 18-55 Years of Age","description":"Placebo: Intramuscular injection"},{"id":"OG003","title":"Low-dose 10 µg, 65-85 Years of Age","description":"BNT162b1: Intramuscular injection"},{"id":"OG004","title":"High-dose 30 µg, 65-85 Years of Age","description":"BNT162b1: Intramuscular injection"},{"id":"OG005","title":"Placebo, 65-85 Years of Age","description":"Placebo: Intramuscular injection"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"24"},{"groupId":"OG002","value":"24"},{"groupId":"OG003","value":"23"},{"groupId":"OG004","value":"23"},{"groupId":"OG005","value":"24"}]}],"classes":[{"title":"7 days after dose 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"24"},{"groupId":"OG002","value":"24"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0.960","lowerLimit":"0.899","upperLimit":"1.025"},{"groupId":"OG001","value":"0.998","lowerLimit":"0.993","upperLimit":"1.002"},{"groupId":"OG002","value":"0.992","lowerLimit":"0.976","upperLimit":"1.008"}]}]},{"title":"21 days after dose 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"24"},{"groupId":"OG002","value":"24"},{"groupId":"OG003","value":"23"},{"groupId":"OG004","value":"23"},{"groupId":"OG005","value":"24"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"75.535","lowerLimit":"45.607","upperLimit":"125.103"},{"groupId":"OG001","value":"76.351","lowerLimit":"48.641","upperLimit":"119.845"},{"groupId":"OG002","value":"0.988","lowerLimit":"0.962","upperLimit":"1.013"},{"groupId":"OG003","value":"16.501","lowerLimit":"8.998","upperLimit":"30.260"},{"groupId":"OG004","value":"52.377","lowerLimit":"30.969","upperLimit":"88.586"},{"groupId":"OG005","value":"0.997","lowerLimit":"0.991","upperLimit":"1.002"}]}]},{"title":"7 days after dose 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"24"},{"groupId":"OG002","value":"24"},{"groupId":"OG003","value":"23"},{"groupId":"OG004","value":"23"},{"groupId":"OG005","value":"24"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"478.186","lowerLimit":"316.204","upperLimit":"723.147"},{"groupId":"OG001","value":"699.755","lowerLimit":"473.456","upperLimit":"1034.219"},{"groupId":"OG002","value":"0.987","lowerLimit":"0.961","upperLimit":"1.014"},{"groupId":"OG003","value":"101.189","lowerLimit":"47.897","upperLimit":"213.776"},{"groupId":"OG004","value":"427.484","lowerLimit":"281.104","upperLimit":"650.090"},{"groupId":"OG005","value":"1.003","lowerLimit":"0.998","upperLimit":"1.008"}]}]},{"title":"21 days after dose 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"24"},{"groupId":"OG002","value":"24"},{"groupId":"OG003","value":"23"},{"groupId":"OG004","value":"23"},{"groupId":"OG005","value":"24"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"843.129","lowerLimit":"696.113","upperLimit":"1021.194"},{"groupId":"OG001","value":"838.640","lowerLimit":"586.916","upperLimit":"1198.328"},{"groupId":"OG002","value":"0.939","lowerLimit":"0.824","upperLimit":"1.070"},{"groupId":"OG003","value":"785.911","lowerLimit":"631.437","upperLimit":"978.175"},{"groupId":"OG004","value":"805.108","lowerLimit":"655.534","upperLimit":"988.810"},{"groupId":"OG005","value":"0.977","lowerLimit":"0.896","upperLimit":"1.065"}]}]},{"title":"Month 3 after dose 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"24"},{"groupId":"OG002","value":"24"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"488.888","lowerLimit":"359.289","upperLimit":"665.234"},{"groupId":"OG001","value":"532.172","lowerLimit":"371.322","upperLimit":"762.699"},{"groupId":"OG002","value":"0.939","lowerLimit":"0.824","upperLimit":"1.070"}]}]},{"title":"Month 6 after dose 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"24"},{"groupId":"OG002","value":"22"},{"groupId":"OG003","value":"23"},{"groupId":"OG004","value":"23"},{"groupId":"OG005","value":"23"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"75.098","lowerLimit":"50.105","upperLimit":"112.558"},{"groupId":"OG001","value":"95.924","lowerLimit":"66.863","upperLimit":"137.614"},{"groupId":"OG002","value":"1.028","lowerLimit":"0.939","upperLimit":"1.126"},{"groupId":"OG003","value":"42.685","lowerLimit":"29.500","upperLimit":"61.762"},{"groupId":"OG004","value":"90.619","lowerLimit":"64.457","upperLimit":"127.399"},{"groupId":"OG005","value":"0.966","lowerLimit":"0.886","upperLimit":"1.054"}]}]},{"title":"Month 12 after dose 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"23"},{"groupId":"OG001","value":"24"},{"groupId":"OG002","value":"23"},{"groupId":"OG003","value":"22"},{"groupId":"OG004","value":"22"},{"groupId":"OG005","value":"23"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"35.898","lowerLimit":"23.326","upperLimit":"55.246"},{"groupId":"OG001","value":"47.053","lowerLimit":"33.587","upperLimit":"65.918"},{"groupId":"OG002","value":"0.936","lowerLimit":"0.817","upperLimit":"1.073"},{"groupId":"OG003","value":"21.169","lowerLimit":"13.164","upperLimit":"34.039"},{"groupId":"OG004","value":"51.688","lowerLimit":"34.959","upperLimit":"76.423"},{"groupId":"OG005","value":"0.842","lowerLimit":"0.664","upperLimit":"1.069"}]}]}]},{"type":"SECONDARY","title":"Fold Increase in Antibody Anti-RBD IgG Antibody Titers, as Compared to Baseline","description":"At Day 7, Day 21 after dose 1, at Day 7, Day 21 after dose 2, and at Month 3, 6, and 12 after dose 1.","populationDescription":"Per Protocol Set (PPS) - all subjects in the Total Vaccinated Cohort (TVC) who had no major protocol violations and completed dose 2. The TVC included all randomized subjects who had received at least one dose of the investigational vaccine/placebo and could provide with effective baseline.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"fold rise","timeFrame":"Up to 12 months following first dose","groups":[{"id":"OG000","title":"Low-dose 10 µg, 18-55 Years of Age","description":"BNT162b1: Intramuscular injection"},{"id":"OG001","title":"High-dose 30 µg, 18-55 Years of Age","description":"BNT162b1: Intramuscular injection"},{"id":"OG002","title":"Placebo, 18-55 Years of Age","description":"Placebo: Intramuscular injection"},{"id":"OG003","title":"Low-dose 10 µg, 65-85 Years of Age","description":"BNT162b1: Intramuscular injection"},{"id":"OG004","title":"High-dose 30 µg, 65-85 Years of Age","description":"BNT162b1: Intramuscular injection"},{"id":"OG005","title":"Placebo, 65-85 Years of Age","description":"Placebo: Intramuscular injection"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"24"},{"groupId":"OG002","value":"24"},{"groupId":"OG003","value":"23"},{"groupId":"OG004","value":"23"},{"groupId":"OG005","value":"24"}]}],"classes":[{"title":"7 days after dose 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"24"},{"groupId":"OG002","value":"24"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.000","lowerLimit":"1.000","upperLimit":"1.000"},{"groupId":"OG001","value":"1.001","lowerLimit":"0.998","upperLimit":"1.005"},{"groupId":"OG002","value":"0.985","lowerLimit":"0.968","upperLimit":"1.003"}]}]},{"title":"21 days after dose 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"24"},{"groupId":"OG002","value":"24"},{"groupId":"OG003","value":"23"},{"groupId":"OG004","value":"23"},{"groupId":"OG005","value":"24"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"261.903","lowerLimit":"167.900","upperLimit":"408.537"},{"groupId":"OG001","value":"246.976","lowerLimit":"172.957","upperLimit":"352.672"},{"groupId":"OG002","value":"0.986","lowerLimit":"0.964","upperLimit":"1.009"},{"groupId":"OG003","value":"51.597","lowerLimit":"28.409","upperLimit":"93.710"},{"groupId":"OG004","value":"150.858","lowerLimit":"74.500","upperLimit":"305.479"},{"groupId":"OG005","value":"1.001","lowerLimit":"0.985","upperLimit":"1.018"}]}]},{"title":"7 days after dose 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"24"},{"groupId":"OG002","value":"24"},{"groupId":"OG003","value":"23"},{"groupId":"OG004","value":"23"},{"groupId":"OG005","value":"24"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"766.291","lowerLimit":"603.470","upperLimit":"973.042"},{"groupId":"OG001","value":"895.886","lowerLimit":"778.927","upperLimit":"1030.407"},{"groupId":"OG002","value":"0.998","lowerLimit":"0.973","upperLimit":"1.023"},{"groupId":"OG003","value":"182.382","lowerLimit":"96.770","upperLimit":"343.735"},{"groupId":"OG004","value":"556.487","lowerLimit":"351.897","upperLimit":"880.024"},{"groupId":"OG005","value":"1.020","lowerLimit":"0.981","upperLimit":"1.059"}]}]},{"title":"21 days after dose 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"24"},{"groupId":"OG002","value":"24"},{"groupId":"OG003","value":"23"},{"groupId":"OG004","value":"23"},{"groupId":"OG005","value":"24"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"994.206","lowerLimit":"935.295","upperLimit":"1056.827"},{"groupId":"OG001","value":"969.249","lowerLimit":"865.101","upperLimit":"1085.934"},{"groupId":"OG002","value":"1.054","lowerLimit":"0.990","upperLimit":"1.122"},{"groupId":"OG003","value":"797.173","lowerLimit":"645.312","upperLimit":"984.773"},{"groupId":"OG004","value":"741.532","lowerLimit":"498.207","upperLimit":"1103.699"},{"groupId":"OG005","value":"0.884","lowerLimit":"0.753","upperLimit":"1.038"}]}]},{"title":"Month 3 after dose 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"24"},{"groupId":"OG002","value":"24"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"804.724","lowerLimit":"659.991","upperLimit":"981.195"},{"groupId":"OG001","value":"814.977","lowerLimit":"706.611","upperLimit":"939.963"},{"groupId":"OG002","value":"1.051","lowerLimit":"0.970","upperLimit":"1.140"}]}]},{"title":"Month 6 after dose 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"24"},{"groupId":"OG002","value":"22"},{"groupId":"OG003","value":"23"},{"groupId":"OG004","value":"23"},{"groupId":"OG005","value":"23"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"164.992","lowerLimit":"123.722","upperLimit":"220.029"},{"groupId":"OG001","value":"181.895","lowerLimit":"145.883","upperLimit":"226.796"},{"groupId":"OG002","value":"1.061","lowerLimit":"0.889","upperLimit":"1.267"},{"groupId":"OG003","value":"69.813","lowerLimit":"47.788","upperLimit":"101.988"},{"groupId":"OG004","value":"104.557","lowerLimit":"65.750","upperLimit":"166.268"},{"groupId":"OG005","value":"0.764","lowerLimit":"0.615","upperLimit":"0.950"}]}]},{"title":"Month 12 after dose 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"23"},{"groupId":"OG001","value":"24"},{"groupId":"OG002","value":"23"},{"groupId":"OG003","value":"22"},{"groupId":"OG004","value":"22"},{"groupId":"OG005","value":"23"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"46.481","lowerLimit":"33.557","upperLimit":"64.383"},{"groupId":"OG001","value":"53.098","lowerLimit":"42.807","upperLimit":"65.863"},{"groupId":"OG002","value":"0.970","lowerLimit":"0.893","upperLimit":"1.053"},{"groupId":"OG003","value":"25.871","lowerLimit":"16.436","upperLimit":"40.724"},{"groupId":"OG004","value":"41.548","lowerLimit":"25.869","upperLimit":"66.729"},{"groupId":"OG005","value":"0.835","lowerLimit":"0.690","upperLimit":"1.010"}]}]}]},{"type":"SECONDARY","title":"Fold Increase in SARS-CoV-2 Neutralizing Antibody Titers (Virus Neutralizing Test), as Compared to Baseline.","description":"At Day 7, Day 21 after dose 1, at Day 7, Day 21 after dose 2, and at Month 3, 6, and 12 after dose 1.","populationDescription":"Per Protocol Set (PPS) - all subjects in the Total Vaccinated Cohort (TVC) who had no major protocol violations and completed dose 2. The TVC included all randomized subjects who had received at least one dose of the investigational vaccine/placebo and could provide with effective baseline.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"fold rise","timeFrame":"Up to 12 months following first dose","groups":[{"id":"OG000","title":"Low-dose 10 µg, 18-55 Years of Age","description":"BNT162b1: Intramuscular injection"},{"id":"OG001","title":"High-dose 30 µg, 18-55 Years of Age","description":"BNT162b1: Intramuscular injection"},{"id":"OG002","title":"Placebo, 18-55 Years of Age","description":"Placebo: Intramuscular injection"},{"id":"OG003","title":"Low-dose 10 µg, 65-85 Years of Age","description":"BNT162b1: Intramuscular injection"},{"id":"OG004","title":"High-dose 30 µg, 65-85 Years of Age","description":"BNT162b1: Intramuscular injection"},{"id":"OG005","title":"Placebo, 65-85 Years of Age","description":"Placebo: Intramuscular injection"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"24"},{"groupId":"OG002","value":"24"},{"groupId":"OG003","value":"23"},{"groupId":"OG004","value":"23"},{"groupId":"OG005","value":"24"}]}],"classes":[{"title":"7 days after dose 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"24"},{"groupId":"OG002","value":"24"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.000","lowerLimit":"1.000","upperLimit":"1.000"},{"groupId":"OG001","value":"1.000","lowerLimit":"1.000","upperLimit":"1.000"},{"groupId":"OG002","value":"1.000","lowerLimit":"1.000","upperLimit":"1.000"}]}]},{"title":"21 days after dose 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"24"},{"groupId":"OG002","value":"24"},{"groupId":"OG003","value":"23"},{"groupId":"OG004","value":"23"},{"groupId":"OG005","value":"24"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3.775","lowerLimit":"2.117","upperLimit":"6.733"},{"groupId":"OG001","value":"2.911","lowerLimit":"1.942","upperLimit":"4.363"},{"groupId":"OG002","value":"1.000","lowerLimit":"1.000","upperLimit":"1.000"},{"groupId":"OG003","value":"1.393","lowerLimit":"1.007","upperLimit":"1.927"},{"groupId":"OG004","value":"2.189","lowerLimit":"1.443","upperLimit":"3.322"},{"groupId":"OG005","value":"1.000","lowerLimit":"1.000","upperLimit":"1.000"}]}]},{"title":"7 days after dose 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"24"},{"groupId":"OG002","value":"24"},{"groupId":"OG003","value":"23"},{"groupId":"OG004","value":"23"},{"groupId":"OG005","value":"24"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"11.314","lowerLimit":"6.301","upperLimit":"20.316"},{"groupId":"OG001","value":"23.973","lowerLimit":"16.309","upperLimit":"35.237"},{"groupId":"OG002","value":"1.000","lowerLimit":"1.000","upperLimit":"1.000"},{"groupId":"OG003","value":"2.871","lowerLimit":"1.738","upperLimit":"4.744"},{"groupId":"OG004","value":"9.879","lowerLimit":"5.267","upperLimit":"18.529"},{"groupId":"OG005","value":"1.000","lowerLimit":"1.000","upperLimit":"1.000"}]}]},{"title":"21 days after dose 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"24"},{"groupId":"OG002","value":"24"},{"groupId":"OG003","value":"23"},{"groupId":"OG004","value":"23"},{"groupId":"OG005","value":"24"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"46.581","lowerLimit":"30.260","upperLimit":"71.705"},{"groupId":"OG001","value":"50.797","lowerLimit":"36.920","upperLimit":"69.889"},{"groupId":"OG002","value":"1.000","lowerLimit":"1.000","upperLimit":"1.000"},{"groupId":"OG003","value":"16.000","lowerLimit":"9.835","upperLimit":"26.031"},{"groupId":"OG004","value":"32.000","lowerLimit":"19.347","upperLimit":"52.927"},{"groupId":"OG005","value":"1.000","lowerLimit":"1.000","upperLimit":"1.000"}]}]},{"title":"Month 3 after dose 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"24"},{"groupId":"OG002","value":"24"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"10.992","lowerLimit":"7.623","upperLimit":"15.849"},{"groupId":"OG001","value":"17.448","lowerLimit":"12.889","upperLimit":"23.620"},{"groupId":"OG002","value":"1.000","lowerLimit":"1.000","upperLimit":"1.000"}]}]},{"title":"Month 6 after dose 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"24"},{"groupId":"OG002","value":"22"},{"groupId":"OG003","value":"23"},{"groupId":"OG004","value":"23"},{"groupId":"OG005","value":"23"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3.268","lowerLimit":"2.255","upperLimit":"4.736"},{"groupId":"OG001","value":"5.496","lowerLimit":"4.077","upperLimit":"7.409"},{"groupId":"OG002","value":"1.000","lowerLimit":"1.000","upperLimit":"1.000"},{"groupId":"OG003","value":"2.000","lowerLimit":"1.444","upperLimit":"2.770"},{"groupId":"OG004","value":"4.122","lowerLimit":"2.661","upperLimit":"6.387"},{"groupId":"OG005","value":"1.000","lowerLimit":"1.000","upperLimit":"1.000"}]}]},{"title":"Month 12 after dose 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"23"},{"groupId":"OG001","value":"24"},{"groupId":"OG002","value":"23"},{"groupId":"OG003","value":"22"},{"groupId":"OG004","value":"22"},{"groupId":"OG005","value":"23"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.572","lowerLimit":"1.205","upperLimit":"2.049"},{"groupId":"OG001","value":"2.378","lowerLimit":"1.781","upperLimit":"3.177"},{"groupId":"OG002","value":"1.000","lowerLimit":"1.000","upperLimit":"1.000"},{"groupId":"OG003","value":"1.208","lowerLimit":"0.995","upperLimit":"1.467"},{"groupId":"OG004","value":"2.416","lowerLimit":"1.631","upperLimit":"3.580"},{"groupId":"OG005","value":"1.000","lowerLimit":"1.000","upperLimit":"1.000"}]}]}]},{"type":"SECONDARY","title":"Seroconversion Rates (SCR) Defined as a Minimum of 4-fold Increase of Antibody Titers, as Compared to Baseline","description":"At Day 7, Day 21 after dose 1, and at Day 7, Day 21 after dose 2.","populationDescription":"Per Protocol Set (PPS) - all subjects in the Total Vaccinated Cohort (TVC) who had no major protocol violations and completed dose 2. The TVC included all randomized subjects who had received at least one dose of the investigational vaccine/placebo and could provide with effective baseline.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","calculatePct":false,"timeFrame":"Up to 21 days after dose 2","groups":[{"id":"OG000","title":"Low-dose 10 µg, 18-55 Years of Age","description":"BNT162b1: Intramuscular injection"},{"id":"OG001","title":"High-dose 30 µg, 18-55 Years of Age","description":"BNT162b1: Intramuscular injection"},{"id":"OG002","title":"Placebo, 18-55 Years of Age","description":"Placebo: Intramuscular injection"},{"id":"OG003","title":"Low-dose 10 µg, 65-85 Years of Age","description":"BNT162b1: Intramuscular injection"},{"id":"OG004","title":"High-dose 30 µg, 65-85 Years of Age","description":"BNT162b1: Intramuscular injection"},{"id":"OG005","title":"Placebo, 65-85 Years of Age","description":"Placebo: Intramuscular injection"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"24"},{"groupId":"OG002","value":"24"},{"groupId":"OG003","value":"23"},{"groupId":"OG004","value":"23"},{"groupId":"OG005","value":"24"}]}],"classes":[{"title":"SCR of SARS-CoV-2 neutralizing antibody - 7 days after dose 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"24"},{"groupId":"OG002","value":"24"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]},{"title":"SCR of SARS-CoV-2 neutralizing antibody - 21 days after dose 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"24"},{"groupId":"OG002","value":"24"},{"groupId":"OG003","value":"23"},{"groupId":"OG004","value":"23"},{"groupId":"OG005","value":"24"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"11"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"8"},{"groupId":"OG005","value":"0"}]}]},{"title":"SCR of SARS-CoV-2 neutralizing antibody - 7 days after dose 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"24"},{"groupId":"OG002","value":"24"},{"groupId":"OG003","value":"23"},{"groupId":"OG004","value":"23"},{"groupId":"OG005","value":"24"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"23"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"11"},{"groupId":"OG004","value":"18"},{"groupId":"OG005","value":"0"}]}]},{"title":"SCR of SARS-CoV-2 neutralizing antibody - 21 days after dose 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"24"},{"groupId":"OG002","value":"24"},{"groupId":"OG003","value":"23"},{"groupId":"OG004","value":"23"},{"groupId":"OG005","value":"24"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"24"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"21"},{"groupId":"OG004","value":"22"},{"groupId":"OG005","value":"0"}]}]},{"title":"SCR of anti-S1 IgG antibody - 7 days after dose 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"24"},{"groupId":"OG002","value":"24"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]},{"title":"SCR of anti-S1 IgG antibody - 21 days after dose 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"24"},{"groupId":"OG002","value":"24"},{"groupId":"OG003","value":"23"},{"groupId":"OG004","value":"23"},{"groupId":"OG005","value":"24"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"24"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"21"},{"groupId":"OG004","value":"22"},{"groupId":"OG005","value":"0"}]}]},{"title":"SCR of anti-S1 IgG antibody - 7 days after dose 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"24"},{"groupId":"OG002","value":"24"},{"groupId":"OG003","value":"23"},{"groupId":"OG004","value":"23"},{"groupId":"OG005","value":"24"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"24"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"22"},{"groupId":"OG004","value":"23"},{"groupId":"OG005","value":"0"}]}]},{"title":"SCR of anti-S1 IgG antibody - 21 days after dose 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"24"},{"groupId":"OG002","value":"24"},{"groupId":"OG003","value":"23"},{"groupId":"OG004","value":"23"},{"groupId":"OG005","value":"24"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"24"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"23"},{"groupId":"OG004","value":"23"},{"groupId":"OG005","value":"0"}]}]},{"title":"SCR of anti-RBD IgG antibody - 7 days after dose 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"24"},{"groupId":"OG002","value":"24"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]},{"title":"SCR of anti-RBD IgG antibody - 21 days after dose 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"24"},{"groupId":"OG002","value":"24"},{"groupId":"OG003","value":"23"},{"groupId":"OG004","value":"23"},{"groupId":"OG005","value":"24"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"24"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"22"},{"groupId":"OG004","value":"22"},{"groupId":"OG005","value":"0"}]}]},{"title":"SCR of anti-RBD IgG antibody - 7 days after dose 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"24"},{"groupId":"OG002","value":"24"},{"groupId":"OG003","value":"23"},{"groupId":"OG004","value":"23"},{"groupId":"OG005","value":"24"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"24"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"23"},{"groupId":"OG004","value":"23"},{"groupId":"OG005","value":"0"}]}]},{"title":"SCR of anti-RBD IgG antibody - 21 days after dose 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"24"},{"groupId":"OG002","value":"24"},{"groupId":"OG003","value":"23"},{"groupId":"OG004","value":"23"},{"groupId":"OG005","value":"24"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"24"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"23"},{"groupId":"OG004","value":"23"},{"groupId":"OG005","value":"0"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"0","timeFrame":"From Day 1 (Dose 1) up to last visit (approximately 12 months after first dose)","description":"Treatment-emergent AEs (TEAEs) are presented, including solicited and unsolicited AEs.\n\nAn TEAE is defined as any AE with an onset date on or after the first dose (if the AE was absent before the first dose) or worsened after the first dose (if the AE was present before the first dose). AEs with an onset date more than 28 days after the last dose will be considered as treatment emergent only if assessed as related to the vaccine (BNT162b1 or placebo) by the investigator.","eventGroups":[{"id":"EG000","title":"Low-dose 10 µg, 18-55 Years of Age","description":"BNT162b1: Intramuscular injection","deathsNumAffected":0,"deathsNumAtRisk":24,"seriousNumAffected":0,"seriousNumAtRisk":24,"otherNumAffected":22,"otherNumAtRisk":24},{"id":"EG001","title":"High-dose 30 µg, 18-55 Years of Age","description":"BNT162b1: Intramuscular injection","deathsNumAffected":0,"deathsNumAtRisk":24,"seriousNumAffected":1,"seriousNumAtRisk":24,"otherNumAffected":24,"otherNumAtRisk":24},{"id":"EG002","title":"Placebo, 18-55 Years of Age","description":"Placebo: Intramuscular injection","deathsNumAffected":0,"deathsNumAtRisk":24,"seriousNumAffected":1,"seriousNumAtRisk":24,"otherNumAffected":7,"otherNumAtRisk":24},{"id":"EG003","title":"Low-dose 10 µg, 65-85 Years of Age","description":"BNT162b1: Intramuscular injection","deathsNumAffected":0,"deathsNumAtRisk":24,"seriousNumAffected":1,"seriousNumAtRisk":24,"otherNumAffected":22,"otherNumAtRisk":24},{"id":"EG004","title":"High-dose 30 µg, 65-85 Years of Age","description":"BNT162b1: Intramuscular injection","deathsNumAffected":0,"deathsNumAtRisk":24,"seriousNumAffected":0,"seriousNumAtRisk":24,"otherNumAffected":24,"otherNumAtRisk":24},{"id":"EG005","title":"Placebo, 65-85 Years of Age","description":"Placebo: Intramuscular injection","deathsNumAffected":0,"deathsNumAtRisk":24,"seriousNumAffected":0,"seriousNumAtRisk":24,"otherNumAffected":9,"otherNumAtRisk":24}],"seriousEvents":[{"term":"Hyperthyroidism","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":24},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":24}]},{"term":"Thyroid mass","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":24},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":24}]},{"term":"Thyroglossal cyst","organSystem":"Congenital, familial and genetic disorders","sourceVocabulary":"MedDRA 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":24},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":24}]},{"term":"Joint dislocation","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":24},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":24}]},{"term":"Humerus fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":24},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":24}]}],"otherEvents":[{"term":"Vaccination site pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":36,"numAffected":21,"numAtRisk":24},{"groupId":"EG001","numEvents":42,"numAffected":23,"numAtRisk":24},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":24},{"groupId":"EG003","numEvents":25,"numAffected":16,"numAtRisk":24},{"groupId":"EG004","numEvents":34,"numAffected":21,"numAtRisk":24},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":24}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":14,"numAffected":14,"numAtRisk":24},{"groupId":"EG001","numEvents":33,"numAffected":21,"numAtRisk":24},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":24},{"groupId":"EG003","numEvents":8,"numAffected":7,"numAtRisk":24},{"groupId":"EG004","numEvents":31,"numAffected":19,"numAtRisk":24},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":24}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":16,"numAffected":13,"numAtRisk":24},{"groupId":"EG001","numEvents":23,"numAffected":16,"numAtRisk":24},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG003","numEvents":3,"numAffected":3,"numAtRisk":24},{"groupId":"EG004","numEvents":10,"numAffected":8,"numAtRisk":24},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":24}]},{"term":"Malaise","organSystem":"General disorders","sourceVocabulary":"MedDRA 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":8,"numAffected":8,"numAtRisk":24},{"groupId":"EG001","numEvents":12,"numAffected":9,"numAtRisk":24},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":24},{"groupId":"EG004","numEvents":5,"numAffected":4,"numAtRisk":24},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":24}]},{"term":"Vaccination site erythema","organSystem":"General disorders","sourceVocabulary":"MedDRA 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":6,"numAtRisk":24},{"groupId":"EG001","numEvents":11,"numAffected":8,"numAtRisk":24},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG003","numEvents":3,"numAffected":3,"numAtRisk":24},{"groupId":"EG004","numEvents":4,"numAffected":4,"numAtRisk":24},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":24}]},{"term":"Vaccination site swelling","organSystem":"General disorders","sourceVocabulary":"MedDRA 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":24},{"groupId":"EG001","numEvents":9,"numAffected":7,"numAtRisk":24},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG004","numEvents":5,"numAffected":5,"numAtRisk":24},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":24}]},{"term":"Chills","organSystem":"General disorders","sourceVocabulary":"MedDRA 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":24},{"groupId":"EG001","numEvents":9,"numAffected":7,"numAtRisk":24},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":24},{"groupId":"EG004","numEvents":5,"numAffected":4,"numAtRisk":24},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":24}]},{"term":"Temperature intolerance","organSystem":"General disorders","sourceVocabulary":"MedDRA 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":24},{"groupId":"EG001","numEvents":7,"numAffected":6,"numAtRisk":24},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG004","numEvents":5,"numAffected":4,"numAtRisk":24},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":24}]},{"term":"Vaccination site discomfort","organSystem":"General disorders","sourceVocabulary":"MedDRA 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":3,"numAtRisk":24},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":24},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":24},{"groupId":"EG004","numEvents":4,"numAffected":3,"numAtRisk":24},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":24}]},{"term":"Vaccination site pruritus","organSystem":"General disorders","sourceVocabulary":"MedDRA 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":2,"numAtRisk":24},{"groupId":"EG001","numEvents":4,"numAffected":3,"numAtRisk":24},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":24},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":24}]},{"term":"Vaccination site induration","organSystem":"General disorders","sourceVocabulary":"MedDRA 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":24},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":24},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":24}]},{"term":"Pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":24},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":24},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":24}]},{"term":"Chest pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":24},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":24}]},{"term":"Peripheral swelling","organSystem":"General disorders","sourceVocabulary":"MedDRA 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":24},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":24}]},{"term":"Vaccination site rash","organSystem":"General disorders","sourceVocabulary":"MedDRA 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":24},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":24}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":12,"numAffected":11,"numAtRisk":24},{"groupId":"EG001","numEvents":25,"numAffected":19,"numAtRisk":24},{"groupId":"EG002","numEvents":3,"numAffected":3,"numAtRisk":24},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":24},{"groupId":"EG004","numEvents":2,"numAffected":2,"numAtRisk":24},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":24}]},{"term":"Dizziness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":24},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":24},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG004","numEvents":7,"numAffected":6,"numAtRisk":24},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":24}]},{"term":"Arthralgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":24},{"groupId":"EG001","numEvents":14,"numAffected":10,"numAtRisk":24},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":24},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG004","numEvents":2,"numAffected":1,"numAtRisk":24},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":24}]},{"term":"Myalgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":2,"numAtRisk":24},{"groupId":"EG001","numEvents":14,"numAffected":10,"numAtRisk":24},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":24},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":24}]},{"term":"Back pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":24},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":24}]},{"term":"Joint swelling","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":24}]},{"term":"Limb discomfort","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":24},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":24}]},{"term":"Muscular weakness","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":24},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":24}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":24},{"groupId":"EG001","numEvents":5,"numAffected":4,"numAtRisk":24},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":24}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":2,"numAtRisk":24},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":24},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":24},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":24},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":24}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":24},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":24}]},{"term":"Eructation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":24},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":24}]},{"term":"Haemorrhoids","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":24},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":24}]},{"term":"Gastrooesophageal reflux disease","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG004","numEvents":2,"numAffected":1,"numAtRisk":24},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":24}]},{"term":"Toothache","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":24},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":24}]},{"term":"Decreased appetite","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":24},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":24},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG004","numEvents":3,"numAffected":3,"numAtRisk":24},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":24}]},{"term":"Nasopharyngitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":24},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":24},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG003","numEvents":3,"numAffected":3,"numAtRisk":24},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":24},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":24}]},{"term":"Cervicitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":24},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":24}]},{"term":"Urethritis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":24},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":24}]},{"term":"Urinary tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":24},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":24}]},{"term":"Laryngeal pain","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":24},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":24}]},{"term":"Nasal obstruction","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":24},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":24}]},{"term":"Oropharyngeal pain","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":24},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":24}]},{"term":"Pulmonary mass","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":24},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":24}]},{"term":"Lymphadenopathy","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":24},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":24}]},{"term":"Neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":24},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":24}]},{"term":"Limb injury","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":24},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":24}]},{"term":"Wound","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":24},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":24}]},{"term":"Blood uric acid increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":24},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":24},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":24},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":24},{"groupId":"EG005","numEvents":2,"numAffected":2,"numAtRisk":24}]},{"term":"Blood pressure increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":24}]},{"term":"Palpitations","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":24},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":24}]},{"term":"Tinnitus","organSystem":"Ear and labyrinth disorders","sourceVocabulary":"MedDRA 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":24},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":24}]},{"term":"Hypothyroidism","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":24},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":24}]},{"term":"Hepatic failure","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":24},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":24}]},{"term":"Nephrolithiasis","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":24},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":24},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":24}]},{"term":"Dysuria","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":24},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":24}]},{"term":"Micturition urgency","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":24},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":24}]},{"term":"Pollakiuria","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":24},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":24}]},{"term":"Pruritus","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":24},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":24},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":24}]},{"term":"Swelling of eyelid","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 23.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":24},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":24},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":24}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true,"otherDetails":"PIs respectively trial sites shall not publish or refer to in writing or orally, in whole or in part, any data, information or materials generated from the study and the services, without the prior written consent of the sponsor."},"pointOfContact":{"title":"BioNTech clinical trials patient information","organization":"BioNTech SE","email":"patients@biontech.de","phone":"+49 6131 9084","phoneExt":"0"}}},"documentSection":{"largeDocumentModule":{"largeDocs":[{"typeAbbrev":"Prot","hasProtocol":true,"hasSap":false,"hasIcf":false,"label":"Study Protocol","date":"2020-08-05","uploadDate":"2022-08-10T10:50","filename":"Prot_000.pdf","size":4159780},{"typeAbbrev":"SAP","hasProtocol":false,"hasSap":true,"hasIcf":false,"label":"Statistical Analysis Plan","date":"2020-10-29","uploadDate":"2022-08-10T10:50","filename":"SAP_001.pdf","size":1005227}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-11-09"},"conditionBrowseModule":{"meshes":[{"id":"D000086382","term":"COVID-19"},{"id":"D018352","term":"Coronavirus Infections"},{"id":"D014777","term":"Virus Diseases"}],"ancestors":[{"id":"D011024","term":"Pneumonia, Viral"},{"id":"D011014","term":"Pneumonia"},{"id":"D012141","term":"Respiratory Tract Infections"},{"id":"D007239","term":"Infections"},{"id":"D003333","term":"Coronaviridae Infections"},{"id":"D030341","term":"Nidovirales Infections"},{"id":"D012327","term":"RNA Virus Infections"},{"id":"D008171","term":"Lung Diseases"},{"id":"D012140","term":"Respiratory Tract Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"D000090982","term":"BNT162 Vaccine"}],"ancestors":[{"id":"D000087503","term":"mRNA Vaccines"},{"id":"D000087504","term":"Nucleic Acid-Based Vaccines"},{"id":"D014614","term":"Vaccines, Synthetic"},{"id":"D011994","term":"Recombinant Proteins"},{"id":"D011506","term":"Proteins"},{"id":"D000602","term":"Amino Acids, Peptides, and Proteins"},{"id":"D014612","term":"Vaccines"},{"id":"D001688","term":"Biological Products"},{"id":"D045424","term":"Complex Mixtures"},{"id":"D000086663","term":"COVID-19 Vaccines"},{"id":"D014765","term":"Viral Vaccines"},{"id":"D000941","term":"Antigens"},{"id":"D001685","term":"Biological Factors"}]}},"hasResults":true}